Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 43
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

  • Palacios-Baena, Z.R.
  • Calvo-Montes, J.
  • Martínez-Martínez, L.
  • Cantón, R.
  • Pitart, Cristina|||0000-0002-3083-7915
  • Bou, German|||0000-0001-8837-0062
  • Pascual, Á.
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Alemán, Araceli
  • Rivera, A.
  • Pintado, Vicente
  • Ruiz-Garbajosa, P.
  • Gracia-Ahufinger, I.
  • Quintano, F.T.
  • Clavijo, E.
  • Arias, M.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Lecuona, M.
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Salamanca-Rivera, Elena
  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Pérez-Vázquez, María
  • Ruiz-Carrascoso, Guillermo
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Mulet, Xavier
  • González-López, Juanjo|||0000-0003-2419-5909
  • Sivianes, Fran
  • Delgado-Valverde, Mercedes
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Canut-Blasco, Andrés
  • Jorge Arribas García
  • Ayestarán, Ignacio
  • Gutiérrez, David
  • Gijón, Desirèe
  • Roca, Ignasi|||0000-0002-1800-1576
  • Nuvials, Xavier|||0000-0002-6648-2394
  • Viñado, Belén|||0000-0001-6212-5886
  • González, Mónica
  • Suberviola Canas, Borja
  • Maria Elicier Cano García
  • Tinajas, Almudena
  • García Bravo, Moises
  • de Tuesta Díaz, Jose Luis
  • Vidal-García, Matxalen
  • Gomáriz Díaz, María
  • Pérez del Molino Bernal, Mª Luisa
  • Coira Nieto, Amparo
  • Rodríguez Tarazona, Raquel Elisa
  • Arenal Andrés, Noelia
  • Paz Vidal, Mª Isabel
  • Rey-Cao, Sonia
  • Martínez Lamas, Lucía
  • Cabezas Fernández, Mª Teresa
  • Cabeza, Mª Isabel
  • Roldán, Carolina
  • Liébana, Carmen
  • Galán Sánchez, Fátima
  • GarcíaSánchez, Federico Juan Manuel
  • Chueca, Natalia|||0000-0002-3420-3290
  • Mora, Laura
  • Martí Salas, Carmina
  • Quesada, Dolores
  • Casabella Pernas, Antonio|||0000-0002-2534-3689
  • Sanchez, Nerea
  • Aldea Mansilla, Carmen
  • Rodríguez Escudero, M. José
  • Huertas, María
  • Gaitán Durán, Jorge
  • Esparcia Rodríguez, Oscar
  • Sainz de Baranda, Caridad
  • Riquelme Bravo, Eva
  • Hernando, Susana
  • Sánchez Arroyo, Rafael
  • Iglesias Nuñez, Nuria
  • Villa, Jennifer
  • Clapés Sanchez, Ester
  • Gimeno, Adelina
  • López Soria, Leyre
  • Barrios Andrés, Jose Luis
  • García Garrote, Fernando
  • Palop, Begoña
  • Valverde Troya, Miriam
  • García-Gonzàlez, Merce
  • Belles, Alba
  • Azcona, José Manuel
  • López-Calleja, Ana Isabel
  • Pérez Moreno, Mar Olga|||0000-0002-4216-4965
  • Fernández Natal, Isabel
  • Garduno Eseverri, Eugenio
  • Sánchez Benito, Rosario
  • de la Iglesia, Pedro
  • Illescas, Soledad
  • Garcia Agudo, Lidia
  • Frasquet, Juan
  • Leiva, José
  • Giner, Salvador
  • López-Urrutia Lorente, Luis
  • Perez Arellano, Jose Luis
  • del Rosario, Cristobal
  • Ortega Lafont, Pilar
  • Martínez Ramírez, Mariela
Background: Community-acquired (CA) and healthcare-associated (HCA) infections caused by carbapenemase-producing Enterobacterales (CPE) are not well characterized. The objective was to provide detailed information about the clinical and molecular epidemiological features of nosocomial, HCA and CA infections caused by carbapenemase-producing Klebsiella pneumoniae (CP-Kp) and Escherichia coli (CP-Ec). Methods: A prospective cohort study was performed in 59 Spanish hospitals from February to March 2019, including the first 10 consecutive patients from whom CP-Kp or CP-Ec were isolated. Patients were stratified according to acquisition type. A multivariate analysis was performed to identify the impact of acquisition type in 30-day mortality. Results: Overall, 386 patients were included (363 [94%] with CP-Kp and 23 [6%] CP-Ec); in 296 patients (76.3%), the CPE was causing an infection. Acquisition was CA in 31 (8.0%) patients, HCA in 183 (47.4%) and nosocomial in 172 (48.3%). Among patients with a HCA acquisition, 100 (54.6%) had been previously admitted to hospital and 71 (38.8%) were nursing home residents. Urinary tract infections accounted for 19/23 (82.6%), 89/130 (68.5%) and 42/143 (29.4%) of CA, HCA and nosocomial infections, respectively. Overall, 68 infections (23%) were bacteremia (8.7%, 17.7% and 30.1% of CA, HCA and nosocomial, respectively). Mortality in infections was 28% (13%, 14.6% and 42.7% of CA, HCA and nosocomial, respectively). Nosocomial bloodstream infections were associated with increased odds for mortality (adjusted OR, 4.00; 95%CI 1.21-13.19). Conclusions: HCA and CA infections caused by CPE are frequent and clinically significant. This information may be useful for a better understanding of the epidemiology of CPE.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Modeling the Number of People Infected With SARS-COV-2 From Wastewater Viral Load in Northwest Spain

  • Vallejo, J. A.
  • Trigo Tasende, Noelia
  • Rumbo-Feal, Soraya
  • Conde-Pérez, Kelly
  • López-Oriona, Ángel
  • Barbeito, Inés
  • Vaamonde, Manuel
  • Tarrío-Saavedra, Javier
  • Reif López, Rubén
  • Ladra, Susana
  • Rodiño-Janeiro, Bruno Kotska
  • Nasser-Ali, Mohammed
  • Cid, Ángeles
  • Veiga, María Carmen
  • Acevedo, Antón
  • Lamora, Carlos
  • Bou, Germán
  • Cao, Ricardo
  • Poza, Margarita
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract] The quantification of the SARS-CoV-2 RNA load in wastewater has emerged as a useful tool to monitor COVID–19 outbreaks in the community. This approach was implemented in the metropolitan area of A Coruña (NW Spain), where wastewater from a treatment plant was analyzed to track the epidemic dynamics in a population of 369,098 inhabitants. Viral load detected in the wastewater and the epidemiological data from A Coruña health system served as main sources for statistical models developing. Regression models described here allowed us to estimate the number of infected people (R2 = 0.9), including symptomatic and asymptomatic individuals. These models have helped to understand the real magnitude of the epidemic in a population at any given time and have been used as an effective early warning tool for predicting outbreaks in A Coruña municipality. The methodology of the present work could be used to develop a similar wastewater-based epidemiological model to track the evolution of the COVID–19 epidemic anywhere in the world where centralized water-based sanitation systems exist., This work was supported by EDAR Bens S.A., A Coruña, Spain [grant references INV04020, INV12120 and INV05921 to MP], the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 funded by the ISCIII, Spain - General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” [grant numbers PI15/00860 to GB, PI17/01482 and PI20/00413 to MP], the GAIN, Xunta de Galicia, Spain [grant number IN607A 2016/22 to GB, ED431C-2016/015 and ED431C-2020/14 to RC, ED431C 2017/58 to SL, ED431G 2019/01 to RC and SL, and ED431C 2017/66 to MCV], MINECO, Spain [grant number MTM2017-82724-R to RC], Ministerio de Ciencia e Innovación, Spain [grant number PID2020-113578RB-100 to RC], and the Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/006 to GB]. The work was also supported by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 - Research and Innovation Framework Programme under grant agreement no 871029. SR-F was financially supported by REIPI RD16/0016/006, KC-P by IN607A 2016/22 and the Spanish Association against Cancer (AECC) and JAV by IN607A 2016/22. Funding for open access charge: Universidade da Coruña/CISUG, EDAR Bens S.A.; INV04020, EDAR Bens S.A.; INV12120, EDAR Bens S.A.; INV05921, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431C-2016/015, Xunta de Galicia; ED431C-2020/14, Xunta de Galicia; ED431C 2017/58, Xunta de Galicia; ED431G 2019/01, Xunta de Galicia; ED431C 2017/66
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Carbapenem Resistance in Acinetobacter nosocomialis and Acinetobacter junii Conferred by Acquisition of blaOXA-24/40 and Genetic Characterization of the Transmission Mechanism between Acinetobacter Genomic Species

  • Lasarte-Monterrubio, Cristina
  • Guijarro, Paula
  • Bellés, Alba
  • Vázquez-Ucha, Juan Carlos
  • Arca-Suárez, Jorge
  • Fernández-Lozano, Carlos
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Carbapenem resistance is increasing among Gram-negative bacteria, including the genus Acinetobacter. This study aimed to characterize, for the first time, the development of carbapenem resistance in clinical isolates of Acinetobacter junii and Acinetobacter nosocomialis conferred by the acquisition of a plasmid-borne blaOXA-24/40 gene and also to characterize the dissemination of this gene between species of Acinetobacter. Carbapenem-resistant A. nosocomialis HUAV-AN66 and A. junii HUAV-AJ77 strains were isolated in the Arnau de Vilanova Hospital (Spain). The genomes were sequenced, and in silico analysis were performed to characterize the genetic environment and the OXA-24/40 transmission mechanism. Antibiotic MICs were determined, and horizontal transfer assays were conducted to evaluate interspecies transmission of OXA-24/40. Carbapenems MICs obtained were ≥64 mg/L for HUAV-AN66 and HUAV-AJ77. Genome analysis revealed the presence in both strains of a new plasmid, designated pHUAV/OXA-24/40, harboring the carbapenem-resistance gene blaOXA-24/40 and flanked by sequences XerC/XerD. pHUAV/OXA-24/40 was successfully transferred from A. nosocomialis and A. junii to a carbapenem-susceptible A. baumannii strain, thus conferring carbapenem resistance. A second plasmid (pHUAV/AMG-R) was identified in both clinical isolates for the successful horizontal transfer of pHUAV/OXA-24/40. blaOXA-24/40-carrying plasmids of the GR12 group and showing high identity with pHUAV/OXA-24/40 were identified in at least 8 Acinetobacter species. In conclusion the carbapenemase OXA-24/40 is described for the first time in A. nosocomialis and A. junii. In both isolates the blaOXA-24/40 gene was located in the GR12 pHUAV/OXA-24/40 plasmid. GR12 plasmids are implicated in the dissemination and spread of carbapenem resistance among Acinetobacter species. IMPORTANCE Acinetobacter baumannii is one of the most relevant pathogens in terms of antibiotic resistance. The main resistance mechanisms are the carbapenem-hydrolyzing class D β-lactamases (CHDLs), especially OXA-23 and OXA-24/40. In addition to A. baumannii, there are other species within the genus Acinetobacter, which in general exhibit much lower resistance rates. In this work we characterize for the first time two clinical isolates of Acinetobacter nosocomialis and Acinetobacter junii, isolated in the same hospital, carrying the carbapenemase OXA-24/40 and displaying high resistance rates to carbapenems. By means of bioinformatics analysis we have also been able to characterize the mechanism by which this carbapenemase is horizontally transferred interspecies of Acinetobacter spp. The dissemination of carbapenemase OXA-24/40 between non-baumannii Acinetobacter species is concerning since it prevents the use of most β-lactam antibiotics in the fight against these resistant isolates., This work was supported by Projects PI17/01482 and PI20/01212 awarded to A.B. and PI18/00501 to G.B., all within in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII - General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The work was also supported by CIBERINF (CIBER de Enfermedades Infecciosas). The study was also funded by project IN607A 2020/05 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) awarded to G.B. and IN607D 2021/12 awarded to A.B. This work was also supported by Planes Nacionales de I+D+i2008 to 2011/2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectiosus Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. J.A.-S.was financially supported by the Rio Hortega program (ISCIII, CM19/00219), J.C.V.-U. was financially supported by the pFIS program (ISCIII, PI17/01482), C.L.-M. was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and P.G.-S. was financially supported by IN607A 2020/05 Grant (Xunta de Galicia), Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606A-2019/029
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Wastewater early warning system for SARS-CoV-2 outbreaks and variants in a Coruña, Spain

  • Trigo Tasende, Noelia
  • Vallejo, J. A.
  • Rumbo-Feal, Soraya
  • Conde-Pérez, Kelly
  • Vaamonde, Manuel
  • López-Oriona, Ángel
  • Barbeito, Inés
  • Nasser-Ali, Mohammed
  • Reif López, Rubén
  • Rodiño-Janeiro, Bruno Kotska
  • Fernández-Álvarez, Elisa
  • Iglesias Corrás, Iago
  • Tarrío-Saavedra, Javier
  • Tomás, Laura
  • Gallego-García, Pilar
  • Posada, David
  • Bou, Germán
  • López-de-Ullibarri, Ignacio
  • Cao, Ricardo
  • Susana, Ladra
  • Poza, Margarita
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract]: Wastewater-based epidemiology has been widely used as a cost-effective method for tracking the COVID-19 pandemic at the community level. Here we describe COVIDBENS, a wastewater surveillance program running from June 2020 to March 2022 in the wastewater treatment plant of Bens in A Coruña (Spain). The main goal of this work was to provide an effective early warning tool based in wastewater epidemiology to help in decision-making at both the social and public health levels. RT-qPCR procedures and Illumina sequencing were used to weekly monitor the viral load and to detect SARS-CoV-2 mutations in wastewater, respectively. In addition, own statistical models were applied to estimate the real number of infected people and the frequency of each emerging variant circulating in the community, which considerable improved the surveillance strategy. Our analysis detected 6 viral load waves in A Coruña with concentrations between 103 and 106 SARS-CoV-2 RNA copies/L. Our system was able to anticipate community outbreaks during the pandemic with 8-36 days in advance with respect to clinical reports and, to detect the emergence of new SARS-CoV-2 variants in A Coruña such as Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529 and BA.2) in wastewater with 42, 30, and 27 days, respectively, before the health system did. Data generated here helped local authorities and health managers to give a faster and more efficient response to the pandemic situation, and also allowed important industrial companies to adapt their production to each situation. The wastewater-based epidemiology program developed in our metropolitan area of A Coruña (Spain) during the SARS-CoV-2 pandemic served as a powerful early warning system combining statistical models with mutations and viral load monitoring in wastewater over time., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Funding for open access charge: Universidade da Coruña/CISUG. This work was supported by EDAR Bens S.A., A Coruña, Spain [grant references INV04020, INV12120, INV05921, and INV148721 to MP], by the National Plan for Scientific Research, Development and Technological Innovation funded by the Institute of Health Carlos III (ISCIII), Spain—General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” [grant references PI15/00860 to GB, PI17/01482, and PI20/00413 to MP], by the Galician Innovation Agency (GAIN) (Xunta de Galicia, Spain) [grant references IN607A 2016/22 to GB, ED431C-2016/015 and ED431C-2020/14 to RC, ED431C 2021/53 to SL and ED431G 2019/01 and COV20/00604 to RC and SL, by Ministry of Economic Affairs and Digital Transformation (MINECO), Spain [grant references MTM2017-82724-R to RC], by the Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0006 to GB], by the “Innova Saúde” Program, (INNOVAMICROLAB project) co-founded by the Galician Healthcare Service (SERGAS) and the Spanish Ministry of Science and Innovation, and by the Spanish Network of Research in Infectious Diseases (CIBERINFEC, ISCIII), and by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 871029. SR-F was financially supported by REIPI RD16/0016/006, KC-P by IN607A 2016/22 and the Spanish Association against Cancer (AECC) and JAV by IN607A 2016/22. DP was funded by grant EPICOVIGAL FONDO SUPERA-COVID19 from Banco Santander-CSIC-CRUE, Spain, and grant CT850A-2 from (Health Knowledge Agency) ACIS SERGAS from the Consellería de Sanidade of Xunta de Galicia, Spain., EDAR Bens S.A.; INV04020, EDAR Bens S.A.; INV12120, EDAR Bens S.A.; INV05921, EDAR Bens S.A.; INV148721, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431C-2016/015, Xunta de Galicia; ED431C-2020/14, Xunta de Galicia; ED431C 2021/53, Xunta de Galicia; ED431G 2019/01, Xunta de Galicia; COV20/00604
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Towards the early detection of β-lactamase-producing Enterobacteriaceae by MALDI-TOF MS analysis

  • Oviaño, Marina
  • Gómara, Marta
  • Barba, María José
  • Revillo, María José
  • Barbeyto, Luis Pedro
  • Bou, Germán
[Abstract] Objectives: Development of a novel MALDI-TOF MS-based method for the rapid detection of ESBL-producing Enterobacteriaceae. Methods: The method was evaluated in terms of sensitivity, specificity and turnaround time regarding the antibiotic used (cefotaxime, ceftazidime, ceftriaxone, cefpodoxime or cefepime) and the performance of the automated MBT STAR-BL software (Bruker Daltonik GmbH, Germany) relative to qualitative interpretation of spectra for detecting β-lactamase resistance by MALDI-TOF MS (Bruker Daltonik) in a collection of 11 isogenic Escherichia coli control strains expressing different β-lactamases. Finally, for clinical validation, β-lactamase activity was determined under previously evaluated conditions in 100 clinical isolates previously characterized by PCR and sequencing. Results: Clinical validation of the assay showed 100% sensitivity and specificity for detecting β-lactam resistance in 30 min by measuring hydrolysis of ceftriaxone (0.50 mg/mL) with the automated MBT STAR-BL software. Regarding the antibiotics evaluated, ceftriaxone yielded 70% more positive results than cefotaxime, 80% more than ceftazidime and 20% more than cefpodoxime, with 100% specificity. Cefepime revealed 100% sensitivity, but only 27% specificity. For the same incubation time, the automated software yielded on average 41% more positive results in relation to detecting resistance than qualitative interpretation of spectra. Conclusions: Our clinical validation of the method proved it to be highly reliable, simple to perform and time saving, transforming β-lactam resistance detection by MALDI-TOF MS into a ready-to-use technique in clinical laboratories., This work was supported by a grant from the Fondo de Investigación Sanitaria (grant number PI15/00860 to G. B.); Plan Nacional de I + D and Instituto de Salud Carlos III (ISCIII), Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0006) co-financed by European Development Regional Fund ‘A Way to Achieve Europe’ ERDF. M. O. is financially supported by the Río Hortega Programme of the ISCIII (CM15/00155). Sociedad Española de Enfermedades Infecciosas y Microbiología Clinica (SEIMC) supported relocation of M. G. to allow this work to be carried out.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

An improved matrix-assisted laser desorption ionization-time of flight mass spectrometry data analysis pipeline for the identification of carbapenemase-producing Klebsiella pneumoniae

  • Gato, Eva
  • Constanso-Conde, Ignacio
  • Candela, Ana
  • Galán, Fátima
  • Rodiño-Janeiro, Bruno Kotska
  • Arroyo, Manuel J.
  • Méndez, Gema
  • Mancera, Luis
  • Alioto, Tyler S.
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Rodríguez-Sánchez, Belén
  • Bou, Germán
  • Oviaño, Marina
[Abstract] The increasing emergence of carbapenemase-producing Klebsiella pneumoniae (CPK) isolates is a global health alarm. Rapid methods that require minimum sample preparation and rapid data analysis are urgently required. Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has recently been used by clinical laboratories for identification of antibiotic-resistant bacteria; however, discrepancies have arisen regarding biological and technical issues. The aim of this study was to standardize an operating procedure and data analysis for identification of CPK by MALDI-TOF MS. To evaluate this approach, a series of 162 K. pneumoniae isolates (112 CPK and 50 non-CPK) were processed in the MALDI BioTyper system (Bruker Daltonik, Germany) following a standard operating procedure. The study was conducted in two stages; the first is denominated the "reproducibility stage" and the second "CPK identification." The first stage was designed to evaluate the biological and technical variation associated with the entire analysis of CPK and the second stage to assess the final accuracy of MALDI-TOF MS for the identification of CPK. Therefore, we present an improved MALDI-TOF MS data analysis pipeline using neural network analysis implemented in Clover MS Data Analysis Software (Clover Biosoft, Spain) that is designed to reduce variability, guarantee interlaboratory reproducibility, and maximize the information selected from the bacterial proteome. Using the random forest (RF) algorithm, 100% of CPK isolates were correctly identified when all the peaks in the spectra were selected as input features and total ion current (TIC) normalization was applied. Thus, we have demonstrated that real-time direct tracking of CPK is possible using MALDI-TOF MS., This work was supported by funding awarded to M.O. through the Competitive Research Call 2019 of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). The research was also funded by the Fondo de Investigación Sanitaria through grants no. PI15/00860 and PI18/00860 to G.B., integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII) and by the Spanish Network of Research in Infectious Diseases (REIPI), grant no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 and funded by the ISCIII, General Subdirection of Assessment and Promotion of the Research, European Regional Development Fund (FEDER) A Way of Making Europe. M.O. was financially supported by the Juan Rodés program (ISCIII-SERGAS, JR18/00006) and E.G. by the research call 2019 of the SEIMC.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii

  • Vázquez-Ucha, Juan Carlos
  • Maneiro Rey, María
  • Martínez Guitián, Marta
  • Buynak, John
  • Bethel, Christopher R.
  • Bonomo, Robert
  • Bou, Germán
  • Poza, Margarita
  • González-Bello, Concepción
  • Beceiro Casas, Alejandro
[Abstract] The number of infections caused by Gram-negative pathogens carrying carbapenemases is increasing, and the group of carbapenem-hydrolyzing class D β-lactamases (CHDLs) is especially problematic. Several clinically important CHDLs have been identified in Acinetobacter baumannii, including OXA-23, OXA-24/40, OXA-58, OXA-143, OXA-235, and the chromosomally encoded OXA-51. The selection and dissemination of carbapenem-resistant A. baumannii strains constitutes a serious global threat. Carbapenems have been successfully utilized as last-resort antibiotics for the treatment of multidrug-resistant A. baumannii infections. However, the spread of OXA carbapenemases is compromising the continued use of these antimicrobials. In response to this clinical issue, it is necessary and urgent to design and develop new specific inhibitors with efficacy against these enzymes. The aim of this work was to characterize the inhibitory activity of LN-1-255 (a 6-alkylidene-2-substituted penicillin sulfone) and compare it to that of two established inhibitors (avibactam and tazobactam) against the most relevant enzymes of each group of class D carbapenemases in A. baumannii. The β-lactamase inhibitor LN-1-255 demonstrated excellent microbiological synergy and inhibition kinetics parameters against all tested CHDLs and a significantly higher activity than tazobactam and avibactam. A combination of carbapenems and LN-1-255 was effective against A. baumannii class D carbapenemases. Docking assays confirmed the affinity of LN-1-255 for the active site of these enzymes. LN-1-255 represents a potential new β-lactamase inhibitor that may have a significant role in eradicating infections caused by A. baumannii isolates carrying CHDLs., This work was financially supported by Planes Nacionales de I+D+i 2008-2011/2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014 and REIPI RD16/0016/006), cofinanced by the European Development Regional Fund “A Way to Achieve Europe” and the operative program Intelligent Growth 2014-2020. This work was also supported by the Galician Innovation Agency (IN607A 2016/22) and the ISCIII-General Subdirection of Assessment and Promotion of the Research (PI15/00860 to G.B. and PI14/00059 to M.P. and A.B.). This study was also supported by the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), the Xunta de Galicia (Centro Singular de Investigación de Galicia Accreditation 2016-2019, EDG431G/09), and the European Union (European Regional Development Fund-ERDF) to C.G.-B. J.C.V.-U. and A.B. were financially supported by the Miguel Servet Programme ISCIII-FEDER (CP13/00226). M.M. thanks the Spanish Ministry of Science and Innovation for her FPU fellowship. M.M.G. was financially supported by the grant “Clara Roy” from the Spanish Society of Clinical Microbiology and Infectious Diseases. Research reported in this publication was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01AI100560, R01AI063517, and R01AI072219 (to R.A.B.) and T32-GM-7250 to Case Western Reserve University, MLW. This study was supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, award number 1I01BX001974, to R.A.B., and by the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development and the Geriatric Research Education and Clinical Center VISN 10 to R.A.B., Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; EDG431G/09, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI100560, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI063517, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI072219, Case Western Reserve University; T32-GM-7250, Cleveland Department of Veterans Affairs; 1I01BX001974, VA Office of Research and Development and the Geriatric Research Education and Clinical Center; VISN 10
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: the SUPERIOR multicentre study

  • García-Fernández, Sergio
  • García-Castillo, María
  • Bou, Germán
  • García Calvo-Montes, Jorge
  • Cercenado, Emilia
  • Delgado-Valverde, Mercedes
  • Pitart, Cristina
  • Mulet, Xavier
  • Tormo, Nuria
  • López-Mendoza, Diego
  • Díaz-Regañón, Jazmín
  • Cantón, Rafael
Multicenter study, [Abstract] Patients in intensive care units (ICUs) present a high risk of developing an infection caused by multidrug-resistant bacteria. Consequently, new antimicrobials and combinations are required. In this study, the activity of ceftolozane/tazobactam (C/T) was evaluated against Enterobacterales (n = 400) and Pseudomonas aeruginosa (n = 80) clinical isolates collected from patients in Spanish ICUs with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Overall susceptibility to C/T in P. aeruginosa isolates by infection type was 95.7% in cUTI (MIC50/90, 1/4 mg/L) and 85.3% in cIAI (MIC50/90, 1/64 mg/L). Activity against P. aeruginosa was maintained regardless of its resistance pattern, confirming that C/T is one of the best antipseudomonal agents along with colistin and amikacin. Susceptibility to C/T in Enterobacterales by infection type was 79.5/81.9% and 89.3/92.3% (EUCAST/CLSI) in cIAI and cUTI isolates, respectively. Activity was excellent against wild-type organisms, with 100% susceptible and inhibited at MIC ≤1 mg/L. Nevertheless, C/T susceptibility decreased against extended-spectrum β-lactamase (ESBL)-producing isolates: Escherichia coli (80.4/84.8% susceptible by EUCAST/CLSI) and Klebsiella pneumoniae (59.1/77.3% susceptible by EUCAST/CLSI). No activity of C/T was observed in carbapenemase-producing isolates. The in vitro activity of C/T observed in this surveillance study suggests that this agent can be considered as a therapeutic option for cUTI and cIAI due to Enterobacterales and P. aeruginosa in ICU patients, particularly when carbapenemase-producing isolates are not involved., This study was funded by MSD Spain and was supported by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases [RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0010 and REIPI RD16/0016/0011], co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (ERDF), Operative program Intelligent Growth 2014–2020. SG-F is supported by a research contract from Instituto de Salud Carlos III, Spain [Rio Hortega program, ref. CM17/00033].
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

In-Depth Analysis of the Role of the Acinetobactin Cluster in the Virulence of Acinetobacter baumannii

  • Conde-Pérez, Kelly
  • Vázquez-Ucha, Juan Carlos
  • Álvarez-Fraga, Laura
  • Ageitos, Lucía
  • Rumbo-Feal, Soraya
  • Martínez Guitián, Marta
  • Trigo Tasende, Noelia
  • Rodríguez, Jaime
  • Bou, Germán
  • Jiménez, Carlos
  • Beceiro Casas, Alejandro
  • Poza, Margarita
[Abstract] Acinetobacter baumannii is a multidrug-resistant pathogen that represents a serious threat to global health. A. baumannii possesses a wide range of virulence factors that contribute to the bacterial pathogenicity. Among them, the siderophore acinetobactin is one of the most important, being essential for the development of the infection. In this study we performed an in-depth analysis of the acinetobactin cluster in the strain A. baumannii ATCC 17978. For this purpose, nineteen individual isogenic mutant strains were generated, and further phenotypical analysis were performed. Individual mutants lacking the biosynthetic genes entA, basG, basC, basD, and basB showed a significant loss in virulence, due to the disruption in the acinetobactin production. Similarly, the gene bauA, coding for the acinetobactin receptor, was also found to be crucial for the bacterial pathogenesis. In addition, the analysis of the ΔbasJ/ΔfbsB double mutant strain demonstrated the high level of genetic redundancy between siderophores where the role of specific genes of the acinetobactin cluster can be fulfilled by their fimsbactin redundant genes. Overall, this study highlights the essential role of entA, basG, basC, basD, basB and bauA in the pathogenicity of A. baumannii and provides potential therapeutic targets for the design of new antivirulence agents against this microorganism., This work was funded by Projects PI15/00860 awarded to GB and PI17/01482 to AB and MP, all within in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII – General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The study was also funded by project IN607A 2016/22 (GAIN- Agencia Gallega de Innovación – Consellería de Economía, Emprego e Industria) awarded to GB. This work was also supported by Planes Nacionales de I + D + i 2008–2011/2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. This work was also supported by Grant RTI2018-093634-B-C22 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, co-funded by the FEDER Programme from the European Union and Xunta de Galicia for the support of Grant ED431E 2018/03 for CICA-INIBIC strategic and the initiative “Seed Projects 2019–2020.” JV-U was financially supported by the ISCIII project FI18/00315, LÁ-F by the ISCIII project PI14/00059 and the IN606B-2018/011, MM-G was financially supported by the Grant Clara Roy (SEIMC, Spanish Society of Clinical Microbiology and Infectious Diseases), KC-P by IN607A 2016/22 and AECC (Asociación Española Contra el Cáncer) predoctoral fellowship and LA by Xunta de Galicia co-funded with the European Social Fund (FSE) of the European Union (ED481A-2019/081), Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606B-2018/011, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED481A-2019/081
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Rapid determination of resistance to antibiotic inhibitors of protein synthesis in Staphylococcus aureus through in situ evaluation of DNase activity

  • Otero, Fátima
  • Santiso, Rebeca
  • López, Isidoro
  • Touzón, Inés
  • Gosálvez, Jaime
  • Bou, Germán
  • Fernández, José Luis
[Abstract] A rapid assay was designed for the detection of resistant strains of Staphylococcus aureus to antibiotic inhibitors of protein synthesis. The assay was based on the fact that a brief cell wall digestion with lysostaphin resulted in fragmentation of the chromosomal DNA by releasing the characteristic DNase stored in the cell wall. DNase activity was ascertained by visualization of the DNA fragments released from the isolated nucleoids. Lysostaphin-released DNase activity was found to be influenced by ribosomal protein synthesis. Inhibition of protein synthesis resulted in the prevention of lysostaphin-DNase induced DNA fragmentation when susceptible clinical strains were incubated with erythromycin, azithromycin, or doxycycline for 2 hr before enzymatic treatment. However, in nonsusceptible strains where protein synthesis was unsuccessfully inhibited, this suppression of lysostaphin-DNase was not, or only very slightly, evident. This assay was highly efficient, identifying resistance to erythromycin and azithromycin with 88-90.9% sensitivity and 100% specificity and with 100% sensitivity and specificity to gentamicin and doxycycline, within a 2 hr and 45 min period., The authors are grateful to Prof. Michael E. Kjelland for revision of the article. This work was supported by the Fondo de Investigaciones Sanitarias (PI14/01346) and REIPI, Spanish Network for Research in Infectious Diseases (Instituto de Salud Carlos III, RD16/0016/0006). This work was also funded by IMI sixth call COMBACTE New Drugs 4 Bad Bugs (ND4BB).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing

  • Arca-Suárez, Jorge
  • Rodiño-Janeiro, Bruno Kotska
  • Pérez Gómez, Astrid
  • Guijarro-Sánchez, Paula
  • Vázquez-Ucha, Juan Carlos
  • Cruz, Fernando
  • Gómez-Garrido, Jéssica
  • Alioto, Tyler S.
  • Álvarez-Tejado, Miguel
  • Gut, Marta
  • Gut, Ivo
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • Bou, Germán
Comparative study, [Abstract] The emergence of 16S rRNA methyltransferases (RMTs) in Gram-negative pathogens bearing other clinically relevant resistance mechanisms, such as carbapenemase-producing Enterobacterales (CPE), is becoming an alarming concern. We investigated the prevalence, antimicrobial susceptibility, resistance mechanisms, molecular epidemiology and genetic support of RMTs in CPE isolates from Spain. This study included a collection of 468 CPE isolates recovered during 2018 from 32 participating Spanish hospitals. MICs were determined using the broth microdilution method, the agar dilution method (fosfomycin) or MIC gradient strips (plazomicin). All isolates were subjected to hybrid whole-genome sequencing (WGS). Sequence types (STs), core genome phylogenetic relatedness, horizontally acquired resistance mechanisms, plasmid analysis and the genetic environment of RMTs were determined in silico from WGS data in all RMT-positive isolates. Among the 468 CPE isolates evaluated, 24 isolates (5.1%) recovered from nine different hospitals spanning five Spanish regions showed resistance to all aminoglycosides and were positive for an RMT (21 RmtF, 2 ArmA and 1 RmtC). All RMT-producers showed high-level resistance to all aminoglycosides, including plazomicin, and in most cases exhibited an extensively drug-resistant susceptibility profile. The RMT-positive isolates showed low genetic diversity and were global clones of Klebsiella pneumoniae (ST147, ST101, ST395) and Enterobacter cloacae (ST93) bearing blaOXA-48, blaNDM-1 or blaVIM-1 carbapenemase genes. RMTs were harboured in five different multidrug resistance plasmids and linked to efficient mobile genetic elements. Our findings highlight that RMTs are emerging among clinical CPE isolates from Spain and their spread should be monitored to preserve the future clinical utility of aminoglycosides and plazomicin., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI15/00860 and PI18/00501 to GB and P17/01482 to AB. MG and IG acknowledge the support of the MEIC through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and co-financing with the European Regional Development Fund [MINECO/FEDER, BIO2015-71792-P]. MG and IG also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d'Empresa i Coneixement and the CERCA Programme. Support was also provided by Planes Nacionales de I+D+i 2013–2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/006] co-financed by the European Regional Development Fund ‘A Way to Achieve Europe’, and the operative Intelligent Growth program 2014–2020. JAS was financially supported by the Fundacion Profesor Novoa Santos through a Post-especialización grant and by the Rio Hortega program [ISCIII-SERGAS, CM19/00219]. MO was financially supported by the Juan Rodés program [ISCIII-SERGAS, JR18/00006]. JCVU was financially supported by the pFIS program [ISCIII, PI17/01482].
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS

  • Hernández-García, Marta
  • García-Castillo, María
  • García-Fernández, Sergio
  • Melo-Cristino, José
  • Pinto, Margarida Feijó
  • Gonçalves, Elsa
  • Alves, Valquíria
  • Vieira, Ana Raquel
  • Ramalheira, Elmano
  • Sancho, Luísa
  • Diogo, José
  • Ferreira, Rui
  • Silva, Tania
  • Chaves, Catarina
  • Bou, Germán
  • Cercenado, Emilia
  • Delgado-Valverde, Mercedes
  • Oliver, Antonio
  • Pitart, Cristina
  • Rodríguez-Lozano, Jesús
  • Tormo, Nuria
  • Romano, Joao
  • Pássaro, Leonor
  • Paixao, Laura
  • López-Mendoza, Diego
  • Díaz-Regañón, Jazmín
  • Cantón, Rafael
[Abstract] Objectives: To analyse the epidemiology, the resistome and the virulome of ceftolozane/tazobactam-susceptible or -resistant Pseudomonas aeruginosa clinical isolates recovered from surveillance studies in Portugal (STEP, 2017-18) and Spain (SUPERIOR, 2016-17). Methods: P. aeruginosa isolates were recovered from intra-abdominal, urinary tract and lower respiratory tract infections in ICU patients admitted to 11 Portuguese and 8 Spanish hospitals. MICs were determined (ISO-standard broth microdilution, EUCAST 2020 breakpoints). A subset of 28 ceftolozane/tazobactam-resistant P. aeruginosa isolates were analysed and compared with 28 ceftolozane/tazobactam-susceptible P. aeruginosa strains by WGS. Results: Clonal complex (CC) 235 (27%) and CC175 (18%) were the most frequent, followed by CC244 (13%), CC348 (9%), CC253 (5%) and CC309 (5%). Inter-hospital clonal dissemination was observed, limited to a geographical region (CC235, CC244, CC348 and CC253 in Portugal and CC175 and CC309 in Spain). Carbapenemases were detected in 25 isolates (45%): GES-13 (13/25); VIM type (10/25) [VIM-2 (4/10), VIM-20 (3/10), VIM-1 (2/10) and VIM-36 (1/10)]; and KPC-3 (2/25). GES-13-CC235 (13/15) and VIM type-CC175 (5/10) associations were observed. Interestingly, KPC-3 and VIM-36 producers showed ceftolozane/tazobactam-susceptible phenotypes. However, ceftolozane/tazobactam resistance was significantly associated with GES-13 and VIM-type carbapenemase production. Six non-carbapenemase producers also displayed ceftolozane/tazobactam resistance, three of them showing known ceftolozane/tazobactam resistance-associated mutations in the PBP3 gene, ftsI (R504C and F533L). Overall, an extensive virulome was identified in all P. aeruginosa isolates, particularly in carbapenemase-producing strains. Conclusions: GES-13-CC235 and VIM type-CC175 were the most frequent MDR/XDR P. aeruginosa clones causing infections in Portuguese and Spanish ICU patients, respectively. Ceftolozane/tazobactam resistance was mainly due to carbapenemase production, although mutations in PBP-encoding genes may additionally be involved., The study was funded by MSD Portugal (protocol VP6918) and MSD Spain (protocol MSD-CEF-2016-01). This study was also supported by Plan Nacional de I + D + i 2013–16 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases [RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0010 and REIPI RD16/0016/0011], co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (EDRF), Operative Program Intelligent Growth 2014–20. M.H.-G. is supported by a research contract from a European Project [IMI-JU-9–2013, Ref. iABC - 115721–2].
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Enhanced antibacterial activity of repurposed Mitomycin C and Imipenem in combination with the lytic phage vB_KpnM-VAC13 against clinical isolates of Klebsiella pneumoniae

  • Pacios Santamaría, Olga
  • Fernández-García, Laura
  • Bleriot Rial, Inés
  • Blasco, Lucía
  • González-Bardanca, Mónica
  • Zamora López, María José
  • Fernández-Cuenca, Felipe
  • Oteo, Jesús
  • Pascual, Álvaro
  • Martínez-Martínez, Luis
  • Domingo-Calap, Pilar
  • Bou, Germán
  • Tomás, María
[Abstract] Klebsiella pneumoniae is an opportunistic Gram-negative pathogen that employs different strategies (resistance and persistence) to counteract antibiotic treatments. This study aimed to search for new means of combatting imipenem-resistant and persister strains of K. pneumoniae by repurposing the anticancer drug mitomycin C as an antimicrobial agent and by combining the drug and the conventional antibiotic imipenem with the lytic phage vB_KpnM-VAC13. Several clinical K. pneumoniae isolates were characterized, and an imipenem-resistant isolate (harboring OXA-245 β-lactamase) and a persister isolate were selected for study. The mitomycin C and imipenem MICs for both isolates were determined by the broth microdilution method. Time-kill curve data were obtained by optical density at 600 nm (OD600) measurement and CFU enumeration in the presence of each drug alone and with the phage. The frequency of occurrence of mutants resistant to each drug and the combinations was also calculated, and the efficacy of the combination treatments was evaluated using an in vivo infection model (Galleria mellonella). The lytic phage vB_KpnM-VAC13 and mitomycin C had synergistic effects on imipenem-resistant and persister isolates, both in vitro and in vivo. The phage-imipenem combination successfully killed the persisters but not the imipenem-resistant isolate harboring OXA-245 β-lactamase. Interestingly, the combinations decreased the emergence of in vitro resistant mutants of both isolates. Combinations of the lytic phage vB_KpnM-VAC13 with mitomycin C and imipenem were effective against the persister K. pneumoniae isolate. The lytic phage-mitomycin C combination was also effective against imipenem-resistant K. pneumoniae strains harboring OXA-245 β-lactamase., This study was funded by grants PI16/01163 and PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research–European Regional Development Fund and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI; RD16/0016/0001, RD16/0016/0006, and RD16/CIII/0004/0002) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC; http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Program (SERGAS and ISCIII). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). O. Pacios and M. López were financially supported by grants IN606A-2020/035 and IN606B-2018/008, respectively (GAIN, Xunta de Galicia), and P. Domingo-Calap was financially supported by the ESCMID Research Grant 20200063.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the rapid detection of antimicrobial resistance mechanisms and beyond

  • Oviaño, Marina
  • Bou, Germán
Review, [Abstract] Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has been successfully applied in recent years for first-line identification of pathogens in clinical microbiology because it is simple to use, rapid, and accurate and has economic benefits in hospital management. The range of clinical applications of MALDI-TOF MS for bacterial isolates is increasing constantly, from species identification to the two most promising applications in the near future: detection of antimicrobial resistance and strain typing for epidemiological studies. The aim of this review is to outline the contribution of previous MALDI-TOF MS studies in relation to detection of antimicrobial resistance and to discuss potential future challenges in this field. Three main approaches are ready (or almost ready) for clinical use, including the detection of antibiotic modifications due to the enzymatic activity of bacteria, the detection of antimicrobial resistance by analysis of the peak patterns of bacteria or mass peak profiles, and the detection of resistance by semiquantification of bacterial growth in the presence of a given antibiotic. This review provides an expert guide for MALDI-TOF MS users to new approaches in the field of antimicrobial resistance detection, especially possible applications as a routine diagnostic tool in microbiology laboratories., This work was supported by the Fondo de Investigación Sanitaria (grant PI15/00860 to G.B.), integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII). The results of this work have been funded by the Spanish Network of Research in Infectious Diseases (REIPI) (grant RD16/0016/0006), integrated in the National Plan for Scientific Research, Development, and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) A Way of Making Europe.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Multiplex real-time PCR-shortTUB assay for detection of the mycobacterium tuberculosis complex in smear-negative clinical samples with low mycobacterial loads

  • Alcaide, Fernando
  • Trastoy, Rocío
  • Moure, Raquel
  • González-Bardanca, Mónica
  • Ambroa, Antón
  • Zamora López, María José
  • Bleriot Rial, Inés
  • Blasco, Lucía
  • Fernández-García, Laura
  • Tato, Marta
  • Bou, Germán
  • Tomás, María
Comparative study, [Abstract] Tuberculosis (TB) remains a major health problem worldwide. Control of TB requires rapid, accurate diagnosis of active disease. However, extrapulmonary TB is very difficult to diagnose because the clinical specimens have very low bacterial loads. Several molecular methods involving direct detection of the Mycobacterium tuberculosis complex (MTBC) have emerged in recent years. Real-time PCR amplification simultaneously combines the amplification and detection of candidate sequences by using fluorescent probes (mainly TaqMan or Molecular Beacons) in automated systems. The multiplex real-time PCR-short assay is performed using locked nucleic acid (LNA) probes (length, 8 to 9 nucleotides) in combination with CodUNG to detect multiple pathogens in clinical samples. In this study, we evaluated the performance of this novel multiplex assay for detecting the MTBC in comparison with that of the conventional culture-based method. The multiplex real-time PCR-shortTUB assay targets two genes, whiB3 (redox-responsive transcriptional regulator) and pstS1 (phosphate-specific transporter), yielding limits of detection (LOD) of 10 copies and 100 copies, respectively, and amplification efficiencies of 92% and 99.7%, respectively. A total of 94 extrapulmonary samples and pulmonary samples with low mycobacterial loads (all smear negative; 75 MTBC culture positive) were analyzed using the test, yielding an overall sensitivity of 88% and a specificity of 95%. For pleural fluid and tissues/biopsy specimens, the sensitivity was 83% and 85%, respectively. In summary, this technique could be implemented in routine clinical microbiology testing to reduce the overall turnaround time for MTBC detection and may therefore be a useful tool for the diagnosis of extrapulmonary tuberculosis and diagnosis using pulmonary samples with low mycobacterial loads., This study was funded by grant PI16/01163 awarded to M. Tomás within the State Plan for R+D+I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research–European Regional Development Fund “A way of Making Europe” and Instituto de Salud Carlos III FEDER, the Spanish Network for Research in Infectious Diseases (REIPI; grants REIPI RD16/0016/0006 and RD16/0016/0011), the Study Group on Mechanisms of Action and Resistance to Antimicrobials-GEMARA and Mycobacterial Infections Study Group–GEIM (SEIMC; http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Program (SERGAS and ISCIII).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain

  • Vázquez-Ucha, Juan Carlos
  • Alonso-García, Isaac
  • Guijarro-Sánchez, Paula
  • Lasarte-Monterrubio, Cristina
  • Álvarez-Fraga, Laura
  • Cendón-Esteve, Arnau
  • Outeda, Michelle
  • Maceiras, Romina
  • Peña-Escolano, Andrea
  • Martínez Guitián, Marta
  • Arca-Suárez, Jorge
  • Bou, Germán
  • Beceiro Casas, Alejandro
Multicenter study, [Abstract] Metallo-β-lactamase (MBL)-producing Enterobacterales are of particular concern because they are widely disseminated and difficult to treat, being resistant to almost all β-lactam antibiotics. Aztreonam is not hydrolysed by MBLs but is labile to serine β-lactamases (SBLs), which are usually co-produced by MBL-producing Enterobacterales. This study investigated the activity of aztreonam in combination with novel β-lactamase inhibitors (BLIs) against a national multi-centre study collection of strains co-producing MBLs and SBLs. Fifty-five clinical isolates co-producing MBLs (41 VIM producers, 10 NDM producers and 4 IMP producers) and SBLs were selected, and whole-genome sequencing (WGS) was performed. The minimum inhibitory concentration (MIC) values of aztreonam, aztreonam/avibactam, aztreonam/relebactam, aztreonam/zidebactam, aztreonam/taniborbactam, aztreonam/vaborbactam and aztreonam/enmetazobactam were determined. β-lactam/BLI resistance mechanisms were analysed by WGS. All BLIs decreased the MIC values of aztreonam for strains that were not susceptible to aztreonam. Aztreonam/zidebactam (MIC ≤1 mg/L for 96.4% of isolates), aztreonam/avibactam (MIC ≤1 mg/L for 92.7% of isolates) and aztreonam/taniborbactam (MIC ≤1 mg/L for 87.3 % of isolates) were the most active combinations. For other aztreonam/BLI combinations, 50-70% of the isolates yielded MIC values ≤1 mg/L. WGS data revealed that mutations in PBP3, defective OmpE35/OmpK35 porins, and the presence of extended-spectrum β-lactamases and class C β-lactamases were some of the resistance mechanisms involved in reduced susceptibility to aztreonam/BLIs. Combinations of aztreonam with new BLIs show promising activity against Enterobacterales co-producing MBLs and SBLs, particularly aztreonam/zidebactam, aztreonam/avibactam and aztreonam/taniborbactam. The present results show that these novel drugs may represent innovative therapeutic strategies by their use in yet-unexplored combinations as solutions for difficult-to-treat infections., This study was funded by Instituto de Salud Carlos III (ISCIII) through Projects N° Exp PI20/01212 and PI18/00501, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2017-2020, and co-funded by European Union – European Regional Development Fund ‘A way to make Europe’. The work was also supported by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB21/13/00055), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. In addition, the study was funded by Project IN607A 2020/05 (Agencia Gallega de Innovación – Consellería de Economía, Emprego e Industria) awarded to GB, and Project IN607D 2021/12 awarded to AB. The work was also supported by Planes Nacionales de I+D+i 2017-2020 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006), co-financed by European Development Regional Fund ‘A way to achieve Europe’ and operative programme Intelligent Growth 2014-2020. JA-S was financially supported by the Juan Rodés programme (ISCIII, JR21/00026), JCV-U was financially supported by IN606B-2022/009 (Xunta de Galicia), CL-M was financially supported by IN606A-2019/029 (Xunta de Galicia) and PI20/01212 (ISCIII), and PG-S was financially supported by IN606A 2021/021 (Xunta de Galicia). AC and MO were financially supported by IN607D 2021/12. IA-G was financially supported by the Río Hortega programme (ISCIII, CM21/00076). LA-F was financially supported by IN606B- 2018/011 (Xunta de Galicia). MM-G was financially supported by RSU.UDC.M505 (Ministerio de Universidades)., Xunta de Galicia; IN606B-2022/009, Xunta de Galicia; IN606A-2019/029, Xunta de Galicia; IN606A 2021/021, Xunta de Galicia; IN606B- 2018/011, Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Occurrence of the p019 gene in the blaKPC-harboring plasmids: adverse clinical impact for direct tracking of KPC-producing Klebsiella pneumoniae by matrix-assisted laser desorption ionization-time of flight mass spectrometry

  • Gato, Eva
  • Constanso-Conde, Ignacio
  • Rodiño-Janeiro, Bruno Kotska
  • Guijarro-Sánchez, Paula
  • Alioto, Tyler S.
  • Arroyo, Manuel J.
  • Méndez, Gema
  • Mancera, Luis
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Bou, Germán
  • Oviaño, Marina
[Abstract] Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has recently been used for the direct detection of KPC-producing isolates by analysis of the 11,109 Da mass peak representing the P019 protein. In this study, we evaluate the presence of the 11,109 Da mass peak in a collection of 435 unduplicated Klebsiella pneumoniae clinical isolates. The prevalence of the P019 peak in the blaKPC K. pneumoniae isolates was 49.2% (32/65). The 11,109 Da mass peak was not observed in any of the other carbapenemase (319) or noncarbapenemase producers (116). Computational analysis of the presence of the p019 gene was performed in the aforementioned carbapenemase-producing K. pneumoniae isolates fully characterized by whole-genome sequencing (WGS) and in a further collection of 1,649 K. pneumoniae genomes included in EuSCAPE. Herein, we have demonstrated that the p019 gene is not exclusively linked to the pKpQil plasmid but that it is present in the following plasmids: IncFIB(K)/IncFII(K)/ColRNAI, IncFIB(pQil), IncFIB(pQil)/ColRNAI, IncFIB(pQil)/IncFII(K), IncFIB(K)/IncFII(K), and IncX3. In addition, we have proven the independent movement of the Tn4401 and the ISKpn31, of which the p019 gene is a component. The absence of the p019 gene was obvious in Col440I, Col(pHAD28), IncFIB(K)/IncX3/IncFII(K), and IncFIB(K)/IncFII(K) plasmids. In addition, we also observed another plasmid in which neither Tn4401 nor ISKpn31 was found, IncP6. In the EuSCAPE, the occurrence of p019 varied from 0% to 100% among the different geographical locations. The adverse clinical impact of the diminished prevalence of the p019 gene within the plasmid encoding KPC-producing Klebsiella pneumoniae puts forward the need for reconsideration when applying this technique in a clinical setting., This study was supported by funding awarded to M.O. throughout the competitive research call 2019 of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). The research was also funded by the Fondo de Investigación Sanitaria (grant numbers PI15/00860, PI18/00860 to G.B.) integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII) and by the Spanish Network of Research in Infectious Diseases (REIPI), number RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation2013 to 2016 and funded by the ISCIII- General Subdirection of Assessment and Promotion of the Research – European Regional Development Fund (FEDER) “A way of making Europe.” M.O. was financially supported by the Juan Rodés program (ISCIII-SERGAS, JR18/00006) and E.G. was financially supported by the research call 2019 of the SEIMC. Clover Biosoft has received funding from the European Union’s Horizon H2020 research and innovation program under grant agreement number 868365.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

In vitro activity of Cefepime-Taniborbactam against Carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain

  • Hernández-García, Marta
  • García-Castillo, María
  • Ruiz-Garbajosa, Patricia
  • Bou, Germán
  • Siller, María
  • Pitart, Cristina
  • Gracia-Ahufinger, Irene
  • Mulet, Xavier
  • Pascual, Álvaro
  • Tormo, Nuria
  • Cantón, Rafael
[Abstract] Novel β-lactam-β-lactamase inhibitor combinations currently approved for clinical use are poorly active against metallo-β-lactamase (MBL)-producing strains. We evaluated the in vitro activity of cefepime-taniborbactam (FTB [formerly cefepime-VNRX-5133]) and comparator agents against carbapenemase-producing Enterobacterales (n = 247) and carbapenem-resistant Pseudomonas species (n = 170) clinical isolates prospectively collected from different clinical origins in patients admitted to 8 Spanish hospitals. FTB was the most active agent in both Enterobacterales (97.6% MICFTB, ≤8/4 mg/L) and Pseudomonas (67.1% MICFTB, ≤8/4 mg/L) populations. The MICFTB was >8 mg/L in 6/247 (2.4%) Enterobacterales isolates (3 KPC-producing Klebsiella pneumoniae isolates, 1 VIM-producing Enterobacter cloacae isolate, 1 IMP-producing E. cloacae isolate, and 1 NDM-producing Escherichia coli isolate) and in 56/170 (32.9%) Pseudomonas isolates, 19 of them carbapenemase producers (15 producers of VIM, 2 of GES, 1 of GES+VIM, and 1 of GES+KPC). Against the Enterobacterales isolates with meropenem MICs of >2 mg/L (138/247), FTB was the most active agent against both serine-β-lactamases (107/138) and MBL producers (31/138) (97.2 and 93.5% MICFTB, ≤8/4 mg/L, respectively), whereas the activity of comparators was reduced, particularly against the MBL producers (ceftazidime-avibactam, 94.4 and 12.9%, meropenem-vaborbactam, 85.0 and 64.5%, imipenem-relebactam, 76.6 and 9.7%, ceftolozane-tazobactam, 1.9 and 0%, and piperacillin-tazobactam, 0 and 0%, respectively). Among the meropenem-resistant Pseudomonas isolates (163/170; MIC, >2 mg/L), the activities of FTB against serine-β-lactamase (35/163) and MBL (43/163) producers were 88.6 and 65.1%, respectively, whereas the susceptibilities of comparators were as follows: ceftazidime-avibactam, 88.5 and 16.0%, meropenem-vaborbactam, 8.5 and 7.0%, imipenem-relebactam, 2.9 and 2.3%, ceftolozane-tazobactam, 0 and 2.3%, and piperacillin-tazobactam, 0 and 0%, respectively. Microbiological results suggest FTB as a potential therapeutic option in patients infected with carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas isolates, including MBL producers., This project was sponsored by Venatorx Pharmaceuticals and has been funded in whole or in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract no. HHSO100201900007C. This study was also supported by Plan Nacional de I+D + i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0008, RD16/0016/0010, and REIPI RD16/0016/0011), cofinanced by the European Development Regional Fund “A Way to Achieve Europe” (ERDF), operative program Intelligent Growth 2014–2020 and CIBER en Enfermedades Infecciosas (CIBERINF) (CB21/13/00084).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

The Role of PemIK (PemK/PemI) Type II TA System from Klebsiella pneumoniae Clinical Strains in Lytic Phage Infection

  • Bleriot Rial, Inés
  • Blasco, Lucía
  • Pacios Santamaría, Olga
  • Fernández-García, Laura
  • Ambroa, Antón
  • López Díaz, María
  • Ortiz-Cartagena, Concha
  • Fernández-Cuenca, Felipe
  • Oteo, Jesús
  • Pascual, Álvaro
  • Martínez-Martínez, Luis
  • Domingo-Calap, Pilar
  • Wood, Thomas K.
  • Tomás, María
[Abstract] Since their discovery, toxin-antitoxin (TA) systems have captivated the attention of many scientists. Recent studies have demonstrated that TA systems play a key role in phage inhibition. The aim of the present study was to investigate the role of the PemIK (PemK/PemI) type II TA system in phage inhibition by its intrinsic expression in clinical strains of Klebsiella pneumoniae carrying the lncL plasmid, which harbours the carbapenemase OXA-48 and the PemK/PemI TA system. Furthermore, induced expression of the system in an IPTG-inducible plasmid in a reference strain of K. pneumoniae ATCC10031 was also studied. The results showed that induced expression of the whole TA system did not inhibit phage infection, whereas overexpression of the pemK toxin prevented early infection. To investigate the molecular mechanism involved in the PemK toxin-mediated inhibition of phage infection, assays measuring metabolic activity and viability were performed, revealing that overexpression of the PemK toxin led to dormancy of the bacteria. Thus, we demonstrate that the PemK/PemI TA system plays a role in phage infection and that the action of the free toxin induces a dormant state in the cells, resulting in inhibition of phage infections., This study was funded by grant PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008-2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research—European Regional Development Fund "A way of Making Europe" and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0001, RD16/0016/0006 and RD16/CIII/0004/0002) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Programme (SERGAS and ISCIII). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). O. Pacios and M. López was financially supported by a grant IN606A-2020/035 and IN606B-2018/008, respectively (GAIN, Xunta de Galicia) and M. Gonzalez-Bardanca was financially supported by the Rio Hortega program (ISCIII, CM20/00198), Xunta de Galicia; IN606A-2020/035, Xunta de Galicia; IN606B-2018/008
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Increased antimicrobial resistance in a novel CMY-54 AmpC-type enzyme with a GluLeu217-218 insertion in the Ω-loop

  • Pérez-Llarena, Francisco J.
  • Vázquez-Ucha, Juan Carlos
  • Kerff, Frédéric
  • Zamorano, Laura
  • Miró, Elisenda
  • Póvoa Cabral, María
  • Fleites, Ana
  • Lantero, Marta
  • Martínez-Martínez, Luis
  • Oliver, Antonio
  • Galleni, Moreno
  • Navarro, Ferrán
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] During a Spanish surveillance study, a natural variant of a CMY-type β-lactamase related to CMY-2 with a GluLeu217-218 insertion in the Ω-loop (designated CMY-54) was found to increase the minimum inhibitory concentractions to β-lactams in a clinical strain of Escherichia coli. The aim of this study was to characterize CMY-54 by genetic, microbiological, and biochemical analysis. The blaCMY-54 gene is encoded by a plasmid of around 100 kb that hybridizes with K and FIB probes. The genetic context of blaCMY-54 and blaCMY-2 genes was found to be very similar. E. coli expressing CMY-54 under isogenic conditions showed a clear fourfold to eightfold increase in MICs to penicillins, cefotaxime, ceftazidime, and aztreonam compared with CMY-2. The catalytic efficiencies of pure CMY-2 and CMY-54 proteins correlated with their microbiological parameters. CMY-2 protein was more resistant to thermal denaturation than CMY-54, indicating that the Ω-loop of CMY-54 may be wider and more relaxed and probably enables better accommodation of these antimicrobials. Otherwise, the higher stabilization of CMY-2 may induce a slight reduction of the dynamics of this enzyme and primarily affect the hydrolysis of some of the bulkiest antibiotics. In summary, the GluLeu217-218 insertion observed in CMY-54 compared to CMY-2 produces a β-lactamase with a distinctive catalytic efficacy for β-lactam antimicrobials likely caused by an increased flexibility slightly affecting the active site shape, highlighting the relevance of single mutations on the hydrolytic spectrum in class C β-lactamases., This work was funded by the European Community, FP7, ID:278232 (MagicBullet) and by the Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0006) – cofinanced by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014–2020. Additional funding was provided by the Fondo de Investigación Sanitaria (grants PI12/00552, PI14/00059, and PI15/00860) and by the ISCIII: CP13/00226. F.K. is a research associate from the FRS-FNRS (Belgium).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)

  • Hernández-García, Marta
  • García-Castillo, María
  • Melo-Cristino, José
  • Pinto, Margarida Feijó
  • Gonçalves, Elsa
  • Alves, Valquíria
  • Vieira, Ana Raquel
  • Ramalheira, Elmano
  • Sancho, Luísa
  • Diogo, José
  • Ferreira, Rui
  • Cruz, Hugo
  • Chaves, Catarina
  • Bou, Germán
  • Cercenado, Emilia
  • Delgado-Valverde, Mercedes
  • Oliver, Antonio
  • Pitart, Cristina
  • Rodríguez-Lozano, Jesús
  • Tormo, Nuria
  • Díaz-Regañón, Jazmín
  • Pássaro, Leonor
  • Duarte, Joana
  • Cantón, Rafael
[Abstract] Objectives: To study the in vitro activity of imipenem/relebactam and comparators and the imipenem/relebactam resistance mechanisms in a Pseudomonas aeruginosa collection from Portugal (STEP, 2017-18) and Spain (SUPERIOR, 2016-17) surveillance studies. Methods: P. aeruginosa isolates (n = 474) were prospectively recovered from complicated urinary tract (cUTI), complicated intra-abdominal (cIAI) and lower respiratory tract (LRTI) infections in 11 Portuguese and 8 Spanish ICUs. MICs were determined (ISO broth microdilution). All imipenem/relebactam-resistant P. aeruginosa isolates (n = 30) and a subset of imipenem/relebactam-susceptible strains (n = 32) were characterized by WGS. Results: Imipenem/relebactam (93.7% susceptible), ceftazidime/avibactam (93.5% susceptible) and ceftolozane/tazobactam (93.2% susceptible) displayed comparable activity. The imipenem/relebactam resistance rate was 6.3% (Portugal 5.8%; Spain 8.9%). Relebactam restored imipenem susceptibility to 76.9% (103/134) of imipenem-resistant isolates, including MDR (82.1%; 32/39), XDR (68.8%; 53/77) and difficult-to-treat (DTR) isolates (67.2%; 45/67). Among sequenced strains, differences in population structure were detected depending on the country: clonal complex (CC)175 and CC309 in Spain and CC235, CC244, CC348 and CC253 in Portugal. Different carbapenemase gene distributions were also found: VIM-20 (n = 3), VIM-1 (n = 2), VIM-2 (n = 1) and VIM-36 (n = 1) in Spain and GES-13 (n = 13), VIM-2 (n = 3) and KPC-3 (n = 2) in Portugal. GES-13-CC235 (n = 13) and VIM type-CC175 (n = 5) associations were predominant in Portugal and Spain, respectively. Imipenem/relebactam showed activity against KPC-3 strains (2/2), but was inactive against all GES-13 producers and most of the VIM producers (8/10). Mutations in genes affecting porin inactivation, efflux pump overexpression and LPS modification might also be involved in imipenem/relebactam resistance. Conclusions: Microbiological results reinforce imipenem/relebactam as a potential option to treat cUTI, cIAI and LRTI caused by MDR/XDR P. aeruginosa isolates, except for GES-13 and VIM producers., The study was funded by MSD Portugal (protocol VP6918) and MSD Spain (protocol MSD-CEF-2016-01). This study was also supported by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0010 and REIPI RD16/0016/0011), co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (ERDF), Operative program Intelligent Growth 2014–2020 and CIBER de Enfermedades Infecciosas (CIBERINFEC) (CB21/13/00084), Instituto de Salud Carlos III, Madrid, Spain.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii

  • Vázquez-Ucha, Juan Carlos
  • Martínez Guitián, Marta
  • Maneiro Rey, María
  • Conde-Pérez, Kelly
  • Álvarez-Fraga, Laura
  • Torrens Ribot, Gabriel
  • Oliver, Antonio
  • Buynak, John
  • Bonomo, Robert
  • Bou, Germán
  • González-Bello, Concepción
  • Poza, Margarita
  • Beceiro Casas, Alejandro
[Abstract] The carbapenem-hydrolyzing class D β-lactamases (CHDLs) are the main mechanism of carbapenem resistance in Acinetobacter baumannii. CHDLs are not effectively inactivated by clinically available β-lactam-type inhibitors. We have previously described the in vitro efficacy of the inhibitor LN-1-255 in combination with carbapenems. The aim of this study was to compare the efficacy of LN-1-255 with that of imipenem in murine pneumonia using A. baumannii strains carrying their most extended carbapenemases, OXA-23 and OXA-24/40. The blaOXA-23 and blaOXA-24/40 genes were cloned into the carbapenem-susceptible A. baumannii ATCC 17978 strain. Clinical isolates Ab1 and JC12/04, producing the enzymes OXA-23 and OXA-24/40, respectively, were used in the study. Pharmacokinetic (PK) parameters were determined. An experimental pneumonia model was used to evaluate the efficacy of the combined imipenem–LN-1-255 therapy. MICs of imipenem decreased between 32- and 128-fold in the presence of LN-1-255. Intramuscular treatment with imipenem–LN-1-255 (30/50 mg/kg) decreased the bacterial burden by (i) 4 and 1.7 log10 CFU/g lung in the infection with the ATCC 17978-OXA-23 and Ab1 strains, respectively, and by (ii) 2.5 and 4.5 log10 CFU/g lung in the infection produced by the ATCC 17978-OXA-24/40 and the JC12/04 strains, respectively. In all assays, combined therapy offered higher protection against pneumonia than that provided by monotherapy. No toxicity was observed in treated mice. Imipenem treatment combined with LN-1-255 treatment significantly reduced the severity of infection by carbapenem-resistant A. baumannii strains carrying CHDLs. Preclinical assays demonstrated the potential of LN-1-255 and imipenem therapy as a new antibacterial treatment., This work has been funded by projects PI15/00860 to G.B., CP13/00226 to A.B., and P14/00059 and PI17/01482 to M.P. and A.B., all of which were integrated into the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe,” The study was also funded by project IN607A 2016/22 (Consellería de Cultura, Educación e Ordenación Universitaria) to G.B. This study was also funded by the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), Xunta de Galicia (Centro Singular de Investigación de Galicia accreditation 2016 to 2019, ED431G/09), and by the European Regional Development Fund (ERDF) to C.G.-B. This work was also supported by Planes Nacionales de I+D+i 2008-2011/2013-2016 and by Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006), cofinanced by the European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. Also, this study was supported in part by funds from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (USA) under award numbers R01AI063517, R01AI072219, and R01AI100560, by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program award 1I01BX001974, and by the Geriatric Research Education and Clinical Center VISN 10 to R.A.B. J.D.B. acknowledges support from the National Institutes of Allergy and Infectious Diseases under award number R15AI142699. J.C.V.-U. was financially supported by the Miguel Servet Programme (CP13/00226; ISCIII, Spain) and by Consellería de Cultura, Educación e Ordenación Universitaria (IN607A 2016/22), and M.M.-G. was financially supported by a Clara Roy grant (Spanish Society of Clinical Microbiology and Infectious Diseases [SEIMC])., Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431G/09, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI063517, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI072219, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI100560, Estados Unidos. National Institutes of Allergy and Infectious Diseases; R15AI142699
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Assessment of activity and resistance mechanisms to cefepime in combination with the novel β-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing enterobacterales

  • Vázquez-Ucha, Juan Carlos
  • Lasarte-Monterrubio, Cristina
  • Guijarro-Sánchez, Paula
  • Oviaño, Marina
  • Álvarez-Fraga, Laura
  • Alonso-García, Isaac
  • Arca-Suárez, Jorge
  • Bou, Germán
  • Beceiro Casas, Alejandro
Multicenter study, [Abstract] The global distribution of carbapenemases such as KPC, OXA-48, and metallo-β-lactamases (MBLs) gives cause for concern, as these enzymes are not inhibited by classical β-lactamase inhibitors (BLIs). The current development of new inhibitors is one of the most promising highlights for the treatment of multidrug-resistant bacteria. The activity of cefepime in combination with the novel BLIs zidebactam, taniborbactam, and enmetazobactam was studied in a collection of 400 carbapenemase-producing Enterobacterales (CPE). The genomes were fully sequenced and potential mechanisms of resistance to cefepime/BLI combinations were characterized. Cefepime resistance in the whole set of isolates was 79.5% (MIC50/90 64/≥128mg/L). The cefepime/zidebactam and cefepime/taniborbactam combinations showed the highest activity (MIC50/90 ≤0.5/1 and ≤0.5/2 mg/L, respectively). Cefepime/zidebactam displayed high activity, regardless of the carbapenemase or extended-spectrum β-lactamase (ESBL) considered (99% of isolates displayed MIC ≤2 mg/L). Cefepime/taniborbactam displayed excellent activity against OXA-48- and KPC-producing Enterobacterales and lower activity against MBL-producing isolates (four strains yielded MICs ≥16 mg/L: 2 NDM producers with an insertion in PBP3, one VIM-1 producer with nonfunctional OmpK35, and one IMP-8 producer). Cefepime/enmetazobactam displayed the lowest activity (MIC50/90 1/≥128 mg/L), with MICs ≥16 mg/L for 49 MBL producers, 40 OXA-48 producers (13 with amino acid changes in OmpK35/36, 4 in PBPs and 11 in RamR) and 25 KPC producers (most with an insertion in OmpK36). These results confirm the therapeutic potential of the new β-lactamase inhibitors, shedding light on the activity of cefepime and BLIs against CPE and resistance mechanisms. The cefepime/zidebactam and cefepime/taniborbactam combinations are particularly highlighted as promising alternatives to penicillin-based inhibitors for the treatment of CPE., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI17/01482 and PI20/01212 for A.B. and PI18/00501 for G.B. integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III, ISCIII).CIBERINF (CIBER de Enfermedades Infecciosas). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), N° RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research–European Regional Development Fund (FEDER) “A way of making Europe.” The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12, A.B. and IN607A 2016/22, G.B.).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales

  • Vázquez-Ucha, Juan Carlos
  • Seoane-Estévez, Alejandro
  • Rodiño-Janeiro, Bruno Kotska
  • González-Bardanca, Mónica
  • Conde-Pérez, Kelly
  • Martínez Guitián, Marta
  • Álvarez-Fraga, Laura
  • Arca-Suárez, Jorge
  • Lasarte-Monterrubio, Cristina
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] Background: Imipenem/relebactam is a novel carbapenem/β-lactamase inhibitor combination, developed to act against carbapenemase-producing Enterobacterales (CPE). Objectives: To assess the in vitro activity of imipenem/relebactam against a Spanish nationwide collection of CPE by testing the susceptibility of these isolates to 16 widely used antimicrobials and to determine the underlying β-lactam resistance mechanisms involved and the molecular epidemiology of carbapenemases in Spain. Materials and methods: Clinical CPE isolates (n = 401) collected for 2 months from 24 hospitals in Spain were tested. MIC50, MIC90 and susceptibility/resistance rates were interpreted in accordance with the EUCAST guidelines. β-Lactam resistance mechanisms and molecular epidemiology were characterized by WGS. Results: For all isolates, high rates of susceptibility to colistin (86.5%; MIC50/90 = 0.12/8 mg/L), imipenem/relebactam (85.8%; MIC50/90 = 0.5/4 mg/L) and ceftazidime/avibactam (83.8%, MIC50/90 = 1/≥256 mg/L) were observed. The subgroups of isolates producing OXA-48-like (n = 305, 75.1%) and KPC-like enzymes (n = 44, 10.8%) were highly susceptible to ceftazidime/avibactam (97.7%, MIC50/90 = 1/2 mg/L) and imipenem/relebactam (100.0%, MIC50/90 = ≤0.25/1 mg/L), respectively. The most widely disseminated high-risk clones of carbapenemase-producing Klebsiella pneumoniae across Spain were found to be ST11, ST147, ST392 and ST15 (mostly associated with OXA-48) and ST258/512 (in all cases producing KPC). Conclusions: Imipenem/relebactam, colistin and ceftazidime/avibactam were the most active antimicrobials against all CPEs. Imipenem/relebactam is a valuable addition to the antimicrobial arsenal used in the fight against CPE, particularly against KPC-producing isolates, which in all cases were susceptible to this combination., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI15/00860, PI18/00860 to G.B. and PI17/01482, PI20/01212 to A.B.) integrated in the Plan Nacional de I + D and funded by the Instituto de Salud Carlos III (ISCIII). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII—General Subdirection of Assessment and Promotion of the Research—European Regional Development Fund (FEDER) ‘A way of making Europe’.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections

  • Alonso-García, Isaac
  • Vázquez-Ucha, Juan Carlos
  • Lasarte-Monterrubio, Cristina
  • González-Mayo, Elena
  • Lada-Salvador, Paula
  • Vela-Fernández, Ramón
  • Aja-Macaya, Pablo
  • Guijarro-Sánchez, Paula
  • Rumbo-Feal, Soraya
  • Muíño-Andrade, María José
  • Fernández González, Ana
  • Martínez Guitián, Marta
  • Beceiro Casas, Alejandro
  • Rodríguez-Iglesias, Manuel
  • Oliver, Antonio
  • Arca-Suárez, Jorge
  • Galán-Sánchez, Fátima
  • Bou, Germán
[Abstract] Objectives: To describe and characterize the emergence of resistance to ceftolozane/tazobactam, ceftazidime/avibactam and imipenem/relebactam in a patient receiving ceftazidime/avibactam treatment for an MDR Pseudomonas aeruginosa CNS infection. Methods: One baseline (PA1) and two post-exposure (PA2 and PA3) isolates obtained before and during treatment of a nosocomial P. aeruginosa meningoventriculitis were evaluated. MICs were determined by broth microdilution. Mutational changes were investigated through WGS. The impact on β-lactam resistance of mutations in blaPDC and mexR was determined through cloning experiments and complementation assays. Results: Isolate PA1 showed baseline resistance mutations in DacB (I354A) and OprD (N142fs) conferring resistance to conventional antipseudomonals but susceptibility to ceftazidime/avibactam, ceftolozane/tazobactam and imipenem/relebactam. Post-exposure isolates showed two divergent ceftazidime/avibactam-resistant phenotypes associated with distinctive mutations affecting the intrinsic P PDC β-lactamase (S254Ins) (PA2: ceftolozane/tazobactam and ceftazidime/avibactam-resistant) or MexAB-OprM negative regulator MexR in combination with modification of PBP3 (PA3: ceftazidime/avibactam and imipenem/relebactam-relebactam-resistant). Cloning experiments demonstrated the role of PDC modification in resistance to ceftolozane/tazobactam and ceftazidime/avibactam. Complementation with a functional copy of the mexR gene in isolate PA3 restored imipenem/relebactam susceptibility. Conclusions: We demonstrated how P. aeruginosa may simultaneously develop resistance and compromise the activity of new β-lactam/β-lactamase inhibitor combinations when exposed to ceftazidime/avibactam through selection of mutations leading to PDC modification and up-regulation of MexAB-OprM-mediated efflux., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI22/01212 for J.A.-S., PI17/01482 and PI20/01212 for A.B., PI21/00017 for A.O., and PI18/00501 and PI21/00704 for G.B. integrated in the Plan Nacional de I1D and funded by the Instituto de Salud Carlos III, ISCIII). This research was also funded by CIBERINFEC, no. CB21/13/00055 and no. CB21/13/00099 (CIBER de Enfermedades Infecciosas), and by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0004 and no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research–European Regional Development Fund (FEDER) ‘A way of making Europe’. The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12 to A.B. and IN607A 2016/22 to G.B.). I.A.-G was financially supported by the Rio Hortega programme (ISCIII, CM21/00076). J.C.V.-U. was financially supported by the ISCIII project FI18/00315. C.L.-M. was financially supported by IN606A-2019/029. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026)., Xunta de Galicia; IN607D2021/12, Xunta de Galicia; IN607A 2016/22
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Mechanisms of bacterial tolerance and persistence in the gastrointestinal and respiratory environments

  • Trastoy, Rocío
  • Manso, Tamara
  • Fernández-García, Laura
  • Blasco, Lucía
  • Ambroa, Antón
  • Pérez del Molino, María Luisa
  • Bou, Germán
  • García-Contreras, Rodolfo
  • Wood, Thomas K.
  • Tomás, María
Review, [Abstract] Pathogens that infect the gastrointestinal and respiratory tracts are subjected to intense pressure due to the environmental conditions of the surroundings. This pressure has led to the development of mechanisms of bacterial tolerance or persistence which enable microorganisms to survive in these locations. In this review, we analyze the general stress response (RpoS mediated), reactive oxygen species (ROS) tolerance, energy metabolism, drug efflux pumps, SOS response, quorum sensing (QS) bacterial communication, (p)ppGpp signaling, and toxin-antitoxin (TA) systems of pathogens, such as Escherichia coli, Salmonella spp., Vibrio spp., Helicobacter spp., Campylobacter jejuni, Enterococcus spp., Shigella spp., Yersinia spp., and Clostridium difficile, all of which inhabit the gastrointestinal tract. The following respiratory tract pathogens are also considered: Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, Burkholderia cenocepacia, and Mycobacterium tuberculosis Knowledge of the molecular mechanisms regulating the bacterial tolerance and persistence phenotypes is essential in the fight against multiresistant pathogens, as it will enable the identification of new targets for developing innovative anti-infective treatments., This study was funded by grants PI13/02390 and PI16/01163, awarded to M. Tomás within the State Plan for R+D+I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and cofinanced by the ISCIII-Deputy General Directorate of Evaluation and Promotion of Research-European Regional Development Fund “A Way of Making Europe” and the Instituto de Salud Carlos III FEDER, Spanish Network for Research in Infectious Diseases (REIPI) (grants RD16/0016/0001 and RD16/0016/0006), as well as the Study Group on Mechanisms of Action and Resistance to Antimicrobials (GEMARA; SEIMC). M. Tomás was financially supported by the Miguel Servet Research Programme (SERGAS and ISCIII). R. Trastoy and L. Fernández-García were financially supported by a postspeciality from the Fundación Novo Santos (CHUAC-SERGAS, Galicia, Spain) and a predoctoral fellowship from the Xunta de Galicia (GAIN, Axencia de Innovación), respectively.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Phenotypic and Genomic Comparison of Klebsiella pneumoniae Lytic Phages: vB_KpnM-VAC66 and vB_KpnM-VAC13

  • Pacios Santamaría, Olga
  • Fernández-García, Laura
  • Bleriot Rial, Inés
  • Blasco, Lucía
  • Ambroa, Antón
  • López Díaz, María
  • Ortiz-Cartagena, Concha
  • Fernández-Cuenca, Felipe
  • Oteo, Jesús
  • Pascual, Álvaro
  • Martínez-Martínez, Luis
  • Domingo-Calap, Pilar
  • Tomás, María
[Abstract] Klebsiella pneumoniae is a human pathogen that worsens the prognosis of many immunocompromised patients. Here, we annotated and compared the genomes of two lytic phages that infect clinical strains of K. pneumoniae (vB_KpnM-VAC13 and vB_KpnM-VAC66) and phenotypically characterized vB_KpnM-VAC66 (time of adsorption of 12 min, burst size of 31.49 ± 0.61 PFU/infected cell, and a host range of 20.8% of the tested strains). Transmission electronic microscopy showed that vB_KpnM-VAC66 belongs to the Myoviridae family. The genomic analysis of the phage vB_KpnM-VAC66 revealed that its genome encoded 289 proteins. When compared to the genome of vB_KpnM-VAC13, they showed a nucleotide similarity of 97.56%, with a 93% of query cover, and the phylogenetic study performed with other Tevenvirinae phages showed a close common ancestor. However, there were 21 coding sequences which differed. Interestingly, the main differences were that vB_KpnM-VAC66 encoded 10 more homing endonucleases than vB_KpnM-VAC13, and that the nucleotidic and amino-acid sequences of the L-shaped tail fiber protein were highly dissimilar, leading to different three-dimensional protein predictions. Both phages differed significantly in their host range. These viruses may be useful in the development of alternative therapies to antibiotics or as a co-therapy increasing its antimicrobial potential, especially when addressing multidrug resistant (MDR) pathogens., This study was funded by grants PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research—European Regional Development Fund “A way of Making Europe” and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0001, RD16/0016/0006 and RD16/CIII/0004/0002) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/ accessed on 1 February 2021) and project PID2020-112835RA-I00 funded by MCIN/AEI /10.13039/501100011033, and project SEJIGENT/2021/014 funded by Conselleria d’Innovació, Universitats, Ciència i Societat Digital (Generalitat Valenciana). M. Tomás was financially supported by the Miguel Servet Research Programme (SERGAS and ISCIII). O. Pacios, L. Fernández-García and M. López were financially supported by the grants IN606A-2020/035, IN606B-2021/013 and IN606B-2018/008, respectively (GAIN, Xunta de Galicia). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). P. Domingo-Calap was financially supported by a Ramón y Cajal contract RYC2019-028015-I funded by MCIN/AEI /10.13039/501100011033, ESF Invest in your future, Generalitat Valenciana; SEJIGENT/2021/014, Xunta de Galicia; IN606A-2020/035, Xunta de Galicia; IN606B-2021/013, Xunta de Galicia; IN606B-2018/008
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Engineering and evaluation of a live-attenuated vaccine candidate with enhanced Type 1 fimbriae expression to optimize protection against Salmonella Typhimurium

  • García, Patricia
  • Rodríguez-Coello, Arianna
  • García-Pose, Andrea
  • Fernández-López, María del Carmen
  • Muras, Andrea
  • Moscoso, Miriam
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] Background:Salmonella Typhimurium is a major zoonotic pathogen, in which type 1 fimbriae play a crucial role in intestinal colonization and immune modulation. This study aimed to improve the protective immunity of a previously developed growth-deficient strain-a double auxotroph for D-glutamate and D-alanine-by engineering the inducible expression of type 1 fimbriae. Methods: PtetA-driven expression of the fim operon was achieved by λ-Red mutagenesis. fimA expression was quantified by qRT-PCR, and fimbriation visualized by transmission electron microscopy. Adhesive properties were evaluated through FimH sequence analysis, yeast agglutination, mannose-binding/inhibition assays, and HT-29 cell adherence. BALB/c mice were immunized orogastrically with IRTA ΔΔΔ or IRTA ΔΔΔ PtetA::fim. Safety and immunogenicity were assessed by clinical monitoring, bacterial load, fecal shedding, ELISA tests, and adhesion/blocking assays using fecal extracts. Protection was evaluated after challenging with wild-type and heterologous strains. Results: IRTA ΔΔΔ PtetA::fim showed robust fimA expression, dense fimbrial coverage, a marked mannose-sensitive adhesive phenotype and enhanced HT-29 attachment. Fimbrial overexpression did not alter intestinal colonization or translocation to mesenteric lymph nodes (mLNs). Immunization elicited a mixed IgG1/IgG2a, significantly increased IgA and IgG against type 1 fimbriae-expressing Salmonella, and enhanced the ability of fecal extracts to inhibit the adherence of wild-type strains. Upon challenge (IRTA wild-type/20220258), IRTA ΔΔΔ PtetA::fim reduced infection burden in the cecum (-1.46/1.47-log), large intestine (-1.35/2.17-log), mLNs (-1.32/0.98-log) and systemic organs more effectively than IRTA ΔΔΔ. Conclusions: Inducible expression of type 1 fimbriae enhances mucosal immunity and protection, supporting their inclusion in next-generation Salmonella vaccines. Future work should assess cross-protection and optimize FimH-mediated targeting for mucosal delivery., This study was supported by a grant from SERGAS (The Galician Healthcare Service) (Programs “InnovaSaude” and “InnovaMicrolab”), the Spanish Network for Research in Infectious Diseases (RD16/0016/0006), CIBER-Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (CB21/13/00055), project PI18/00501, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (ERDF/ESF, “A way to make Europe”/”Investing in your future”) and PI21/00704, funded by ISCIII and co-funded by the European Union, awarded to GB. This research was also supported by Projects PI20/01212 and PI23/00851 awarded to A.B., funded by ISCIII and co-funded by the European Union, and by project IN607D 2021/12 awarded to A.B., funded by GAIN-Agencia Gallega de Innovación, Consellería de Economía, Emprego e Industria. A.R was supported by a predoctoral fellowship from the Instituto de Salud Carlos III (FI24/00178). A.M. was supported by a postdoctoral fellowship from the Instituto de Salud Carlos III (CD23/00057).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Antimicrobial activity of Cefiderocol against the Carbapenemase-producing Enterobacter cloacae complex and characterization of reduced susceptibility associated with Metallo-β-Lactamase VIM-1

  • Lasarte-Monterrubio, Cristina
  • Guijarro-Sánchez, Paula
  • Vázquez-Ucha, Juan Carlos
  • Alonso-García, Isaac
  • Álvarez-Fraga, Laura
  • Outeda-García, Michelle
  • Martínez Guitián, Marta
  • Peña-Escolano, Andrea
  • Maceira, Romina
  • Lence, Emilio
  • González-Bello, Concepción
  • Arca-Suárez, Jorge
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Emergence of cefiderocol resistance among carbapenemase-producing Enterobacterales, particularly those in the Enterobacter cloacae complex (ECC), is becoming of alarming concern; however, the mechanistic basis of this phenomenon remains poorly understood. We describe the acquisition of VIM-1-mediated reduced cefiderocol susceptibility (MICs 0.5 to 4 mg/L) in a collection of 54 carbapenemase-producing isolates belonging to the ECC. MICs were determined by reference methodologies. Antimicrobial resistance genomic analysis was performed through hybrid WGS. The impact of VIM-1 production on cefiderocol resistance in the ECC background was examined at microbiological, molecular, biochemical, and atomic levels. Antimicrobial susceptibility testing yielded 83.3% susceptible isolates and MIC50/90 values of 1/4 mg/L. Decreased susceptibility to cefiderocol was mainly associated with isolates producing VIM-1, with cefiderocol MICs 2- to 4-fold higher than for isolates carrying other types of carbapenemases. E. cloacae and Escherichia coli VIM-1 transformants displayed significantly enhanced cefiderocol MICs. Biochemical assays with purified VIM-1 protein revealed low but detectable cefiderocol hydrolysis. Simulation studies revealed how cefiderocol is anchored to the VIM-1 active site. Additional molecular assays and WGS data analysis highlighted the implication of SHV-12 coproduction and suggested the inactivation of the FcuA-like siderophore receptor as further contributors to the higher cefiderocol MICs. Our findings warn of the potential of the VIM-1 carbapenemase to at least partly limit the activity of cefiderocol in the ECC. This effect is probably enhanced due to combination with additional mechanisms, such as ESBL production and siderophore inactivation, and indicates the need for active surveillance to extend the life span of this promising cephalosporin., This research was supported by Projects PI17/01482 and PI20/01212 awarded to AB, PI22/01212 to JAS and PI18/00501 to GB, within in the National Plan for Scientific Research, Development and Technological Innovation 2017 to 2020 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The work was also supported by CIBERINFEC (CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III). The study was also funded by project IN607A 2020/05 (GAIN-Agencia Gallega de Innovación-Consellería de Economía, Emprego e Industria) awarded to GB and project IN607D 2021/12 awarded to AB. It was also supported by Planes Nacionales de I+D+i2017 to 2020 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth2014 to 2020. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026), J.C.V.-U. was financially supported by IN606B-2022/009 Grant (Xunta de Galicia), C.L.-M. was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and PGS was financially supported by IN606A 2021/021 Grant (Xunta de Galicia). M.O. was financially supported by IN607D 2021/12 (Xunta de Galicia). I.A.-G. was financially supported by the Rio Hortega program (ISCIII, CM21/00076). C.G.-B. acknowledges financial support from the Spanish Ministry of Science and Innovation (PID2019-105512RB-I00), the Xunta de Galicia (ED431C 2021/29 and the Centro singular de investigación de Galicia accreditation2019 to 2022 [ED431G 2019/03]), and the European Regional Development Fund (ERDF)., Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606B-2022/009, Xunta de Galicia; IN606A-2019/029, Xunta de Galicia; IN606A 2021/021, Xunta de Galicia; ED431C 2021/29, Xunta de Galicia; ED431G 2019/03
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Marine Organisms from the Yucatan Peninsula (Mexico) as a Potential Natural Source of Antibacterial Compounds

  • Pech-Puch, Dawrin
  • Pérez Povedano, Mar Anabel
  • Gómez, Patricia
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Vázquez-Ucha, Juan Carlos
  • Novoa Olmedo, María Lourdes
  • Guillén-Hernández, Sergio
  • Villegas-Hernández, Harold
  • Bou, Germán
  • Rodríguez, Jaime
  • Beceiro Casas, Alejandro
  • Jiménez, Carlos
[Abstract] A total of 51 sponges (Porifera) and 13 ascidians (Chordata) were collected on the coast of the Yucatan Peninsula (Mexico) and extracted with organic solvents. The resulting extracts were screened for antibacterial activity against four multidrug-resistant (MDR) bacterial pathogens: the Gram-negative Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa and the Gram-positive Staphylococcus aureus. The minimum inhibitory concentrations (MICs) of the organic extracts of each marine organism were determined using a broth microdilution assay. Extracts of eight of the species, in particular the Agelas citrina and Haliclona (Rhizoniera) curacaoensis, displayed activity against some of the pathogens tested. Some of the extracts showed similar MIC values to known antibiotics such as penicillins and aminoglycosides. This study is the first to carry out antimicrobial screening of extracts of marine sponges and ascidians collected from the Yucatan Peninsula. Bioassay-guided fractionation of the active extracts from the sponges Amphimedon compressa and A. citrina displayed, as a preliminary result, that an inseparable mixture of halitoxins and amphitoxins and (-)-agelasine B, respectively, are the major compounds responsible for their corresponding antibacterial activities. This is the first report of the antimicrobial activity of halitoxins and amphitoxins against major multidrug-resistant human pathogens. The promising antibacterial activities detected in this study indicate the coast of Yucatan Peninsula as a potential source of a great variety of marine organisms worthy of further research., This work was supported by Grants RTI2018-093634-B-C22 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, co-funded by the FEDER Programme from the European Union, by projects PI15/00860 and PI18/00501 to GB and PI14/00059 and PI17/01482 to AB (Instituto de Salud Carlos III) and BLUEBIOLAB (0474_BLUEBIOLAB_1_E), Programme INTERREG V A of Spain-Portugal (POCTEP). The study was also funded by projects IN607A 2016/22 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) and GRC2018/039 and Agrupación Estratégica CICA-INIBIC ED431E 2018/03 (Consellería de Educación, Universidades e Formación Profesional) from the Xunta de Galicia (autonomous government of the region). Support was also provided by Planes Nacionales de I+D+i 2013-2016 and ISCIII, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by European Development Regional Fund "A way to achieve Europe" and the operative program Intelligent Growth 2014-2020. J.C.V.U. was financially supported by the pFIS Programme (FI18/00315), M.M.G. was financially supported by a Clara Roy grant (SEIMC) and C.L.M. by IN606A-2019/029. D.P.P. received a fellowship from the program National Council of Science and Technology (CONACYT) of Mexico and the Secretariat of Research, Innovation and Higher Education (SIIES) of Yucatan (Mexico), Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; GRC2018/039, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606A-2019/029
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Kpi, a Chaperone-Usher Pili System Associated with the Worldwide-Disseminated High-Risk Clone Klebsiella Pneumoniae ST-15

  • Gato, Eva
  • Vázquez-Ucha, Juan Carlos
  • Rumbo-Feal, Soraya
  • Álvarez-Fraga, Laura
  • Vallejo, J. A.
  • Martínez Guitián, Marta
  • Beceiro Casas, Alejandro
  • Ramos Vivas, Jose
  • Sola-Campoy, Pedro Juan
  • Pérez-Vázquez, María
  • Oteo, Jesús
  • Rodiño-Janeiro, Bruno Kotska
  • Romero, A.
  • Poza, Margarita
  • Bou, Germán
  • Pérez Gómez, Astrid
[Abstract] Control of infections caused by carbapenem-resistant Klebsiella pneumoniae continues to be challenging. The success of this pathogen is favored by its ability to acquire antimicrobial resistance and to spread and persist in both the environment and in humans. The emergence of clinically important clones, such as sequence types 11, 15, 101, and 258, has been reported worldwide. However, the mechanisms promoting the dissemination of such high-risk clones are unknown. Unraveling the factors that play a role in the pathobiology and epidemicity of K. pneumoniae is therefore important for managing infections. To address this issue, we studied a carbapenem-resistant ST-15 K. pneumoniae isolate (Kp3380) that displayed a remarkable adherent phenotype with abundant pilus-like structures. Genome sequencing enabled us to identify a chaperone-usher pili system (Kpi) in Kp3380. Analysis of a large K. pneumoniae population from 32 European countries showed that the Kpi system is associated with the ST-15 clone. Phylogenetic analysis of the operon revealed that Kpi belongs to the little-characterized γ2-fimbrial clade. We demonstrate that Kpi contributes positively to the ability of K. pneumoniae to form biofilms and adhere to different host tissues. Moreover, the in vivo intestinal colonizing capacity of the Kpi-defective mutant was significantly reduced, as was its ability to infect Galleria mellonella. The findings provide information about the pathobiology and epidemicity of Kpi+ K. pneumoniae and indicate that the presence of Kpi may explain the success of the ST-15 clone. Disrupting bacterial adherence to the intestinal surface could potentially target gastrointestinal colonization., This research was supported by Projects p-01216A and IJCI-2016-29524 (to A.P.), funded by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Minestry of Economy and Competetiveness (MINECO), respectively. It was also supported by Projects PI11/01034 (to M.P.), PI14/00059 and PI17/1482 (to M.P. and A.B.), and PI18/00501 (to G.B.), included in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 and funded by the Instituto de Salud Carlos III (ISCIII) and Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014-2020. Grant BFU2016-77835-R of the MINECO (to A.R.) also supported this research. E.G. was financially supported by the SEIMC project. J.C.V.-U. was financially supported by the PFIS (Contratos Predoctorales de Formación en Investigación en Salud) program (F18/00315); J.A.V. was financially supported by IN607A 2016/22; M.M.-G. was financially supported by a Clara Roy grant (SEIMC); A.B. was financially supported by the Miguel Servet program (ISCIII, Spain); B.K.R.-J. was financially supported by Marie S. Curie Action SaPhaDe project (MSCA-IF-GF-836754); and A.P. was financially supported by the Juan de la Cierva program (MINECO, IJCI-2016-29524), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; p-01216A, Xunta de Galicia; IN607A 2016/22
RUC. Repositorio da Universidade da Coruña
Publicación Tesis doctoral (DoctoralThesis)

Detección rápida de resistencia bacteriana a antibióticos mediante microscopía de fluorescencia

  • López Baltar, Isidoro
[Resumo] A resistencia bacteriana aos antibióticos é un grave problema de saúde mundial. En situacións críticas, a prescrición rápida do antibiótico axeitado é esencial. Polo tanto, sería de grande interese dispor de procedementos de detección de resistencia que sexan máis rápidos que os antibiogramas estándar, que dependen da avaliación do crecemento bacteriano. Esta tese continúa a liña de exploración, deseño e validación de posibles características fenotípicas-morfolóxicas simples, visibles mediante microscopía de fluorescencia, que permitan a detección rápida e fiable da resistencia a diferentes antibióticos en patóxenos con alto impacto clínico. No caso do cotrimoxazol, en Escherichia coli e Klebsiella pneumoniae, avaliouse a prevención ou non de alongamento celular inducido por mitomicina C. A prevención ou non da actividade da DNase nos nucleoides bacterianos foi eficaz na caracterización de diferentes antibióticos inhibidores da síntese de proteínas en Staphyloccocus aureus. Finalmente, para a mestura combinada de ciprofloxacino (quinolona) e ampicilina (betalactámico) en E. coli, a sensibilidade/resistencia a cada antibiótico determinouse simultaneamente estimando a condensación ou non do nucleoide (ciprofloxacino) e a presenza ou non de fragmentos de ADN intercelular (ampicilina). Os resultados foron consistentes cos do antibiograma estándar e obtivéronse nun prazo de 60 a 270 minutos., [Resumen] La resistencia bacteriana a los antibióticos es un grave problema sanitario a nivel mundial. En situaciones críticas es importante la prescripción rápida del antibiótico idóneo. Para ello sería de gran interés disponer de procedimientos de detección de resistencias, más rápidos que los antibiogramas estándar, dependientes de la evaluación del crecimiento bacteriano. En esta tesis se continúa la línea de exploración, diseño y validación, de posibles características fenotípicas-morfológicas simples, visibles mediante microscopía de fluorescencia, que permitan la detección rápida y fiable de resistencia a diferentes antibióticos en patógenos de gran impacto clínico. En el caso del cotrimoxazol, en Escherichia coli y Klebsiella pneumoniae, se evaluó la prevención o no del alargamiento celular inducido por mitomicina C. La afectación o no de la actividad ADNasa sobre los nucleoides bacterianos, fue efectiva para caracterizar diferentes antibióticos inhibidores de la síntesis de proteínas, en Staphyloccocus aureus. Finalmente, para la mezcla conjunta de ciprofloxacino (quinolona) y ampicilina (betalactámico) en E. coli, se logró discriminar simultáneamente la sensibilidad/resistencia a cada antibiótico, estimando la condensación o no del nucleoide (ciprofloxacino) y la presencia o no de fragmentos de ADN intercelular (ampicilina). Los resultados concordaron con los del antibiograma estándar, obteniéndose en tiempos entre 60 y 270 minutos., [Abstract] Bacterial resistance to antibiotics is a serious global health problem. In critical situations, the rapid prescription of the appropriate antibiotic is essential. Therefore, it would be of great interest to have available resistance detection procedures that are faster than standard antibiograms, which depend on the evaluation of bacterial growth. This thesis continues the line of exploration, design, and validation of possible simple phenotypic-morphological characteristics, visible using fluorescence microscopy, that allow for the rapid and reliable detection of resistance to different antibiotics in pathogens with high clinical impact. In the case of cotrimoxazole, in Escherichia coli and Klebsiella pneumoniae, the prevention or not of mitomycin C-induced cell elongation, was evaluated. The prevention or not of DNase activity on bacterial nucleoids was effective in characterizing different protein synthesis-inhibiting antibiotics in Staphyloccocus aureus. Finally, for the combined mixture of ciprofloxacin (quinolone) and ampicillin (beta-lactam) in E. coli, sensitivity/resistance to each antibiotic was simultaneously determined by estimating the condensation or not of the nucleoid (ciprofloxacin) and the presence or not of intercellular DNA fragments (ampicillin). The results were consistent with those of the standard antibiogram, and were obtained within 60 to 270 minutes., Los trabajos que han dado lugar a esta tesis han sido financiados por los proyectos que se señalan a continuación: - PI14/01346. “Desarrollo y validación de un procedimiento sim-ple para la determinación rápida de la resistencia bacteriana a antibióticos inhibidores de la síntesis de proteínas”. Fondo de Investigaciones Sanitarias (FIS). (187.852,50 euros). Años 2015-2017. Prorrogado hasta marzo de 2019. - RD16/0016/0006. “Red temática de investigaciones coopera-tiva: Red española de investigación en patología infecciosa”. Años 2013-2016 y 2017-2022. - PI20/01263. “Desarrollo de un nuevo procedimiento simple y rápido para determinar la sensibilidad/resistencia bacteriana a quinolonas y sus combinaciones con beta-lactámicos, de modo simultáneo e independiente. Fondo de Investigaciones Sanita-rias (FIS). (99.220 euros). Años 2021-2023. Prorrogado hasta 2024. - CB21/13/00055. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas Instituto de Salud Carlos III (ISCIII) 01/01/2021 60.000 €.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

(p)ppGpp and its role in bacterial persistence: new challenges

  • Pacios Santamaría, Olga
  • Blasco, Lucía
  • Bleriot Rial, Inés
  • Fernández-García, Laura
  • Ambroa, Antón
  • Zamora López, María José
  • Bou, Germán
  • Cantón, Rafael
  • García-Contreras, Rodolfo
  • Wood, Thomas K.
  • Tomás, María
Review, [Abstract] Antibiotic failure not only is due to the development of resistance by pathogens but can also often be explained by persistence and tolerance. Persistence and tolerance can be included in the "persistent phenotype," with high relevance for clinics. Two of the most important molecular mechanisms involved in tolerance and persistence are toxin-antitoxin (TA) modules and signaling via guanosine pentaphosphate/tetraphosphate [(p)ppGpp], also known as "magic spot." (p)ppGpp is a very important stress alarmone which orchestrates the stringent response in bacteria; hence, (p)ppGpp is produced during amino acid or fatty acid starvation by proteins belonging to the RelA/SpoT homolog family (RSH). However, (p)ppGpp levels can also accumulate in response to a wide range of signals, including oxygen variation, pH downshift, osmotic shock, temperature shift, or even exposure to darkness. Furthermore, the stringent response is not only involved in responses to environmental stresses (starvation for carbon sources, fatty acids, and phosphates or heat shock), but it is also used in bacterial pathogenesis, host invasion, and antibiotic tolerance and persistence. Given the exhaustive and contradictory literature surrounding the role of (p)ppGpp in bacterial persistence, and with the aim of summarizing what is known so far about the magic spot in this bacterial stage, this review provides new insights into the link between the stringent response and persistence. Moreover, we review some of the innovative treatments that have (p)ppGpp as a target, which are in the spotlight of the scientific community as candidates for effective antipersistence agents., This study was funded by grant PI16/01163 and PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008-2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research–European Regional Development Fund, A way of Making Europe, Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0006 and RD16/0016/0011), and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/). M. Tomás was financially supported by the Miguel Servet Research Program (SERGAS and ISCIII). L. Fernández-García was supported by postdoctoral fellowship from the Diputation A Coruña (Xunta Galicia). T.J.K. is supported by a National Health and Medical Research Council Early Career Fellowship (GNT1088448).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial

  • Pérez Gómez, Astrid
  • Gato, Eva
  • Pérez-Llarena, Francisco J.
  • Fernández-Cuenca, Felipe
  • Gude, María José
  • Oviaño, Marina
  • Pachón, María Eugenia
  • Garnacho-Montero, José
  • González-Galán, Verónica
  • Pascual, Álvaro
  • Cisneros, José Miguel
  • Bou, Germán
[Abstract] Objectives: To characterize the antimicrobial susceptibility, molecular epidemiology and carbapenem resistance mechanisms in Pseudomonas aeruginosa isolates recovered from respiratory tract samples from patients with ventilator-associated pneumonia enrolled in the MagicBullet clinical trial. Methods: Isolates were collected from 53 patients from 12 hospitals in Spain, Italy and Greece. Susceptibility was determined using broth microdilution and Etest. MALDI-TOF MS was used to detect carbapenemase activity and carbapenemases were identified by PCR and sequencing. Molecular epidemiology was investigated using PFGE and MLST. Results: Of the 53 isolates, 2 (3.8%) were considered pandrug resistant (PDR), 19 (35.8%) were XDR and 16 (30.2%) were MDR. Most (88.9%) of the isolates from Greece were MDR, XDR or PDR, whereas fewer of the isolates from Spain (33.3%) and Italy (43.5%) showed antibiotic resistance. Three Greek isolates were resistant to colistin. Overall, the rates of resistance of P. aeruginosa isolates to imipenem, ciprofloxacin, ceftolozane/tazobactam and ceftazidime/avibactam were 64.1%, 54.7%, 22.6% and 24.5%, respectively. All isolates resistant to ceftolozane/tazobactam and ceftazidime/avibactam (Greece, n = 10; and Italy, n = 2) carried blaVIM-2. Spanish isolates were susceptible to the new drug combinations. Forty-eight restriction patterns and 27 STs were documented. Sixty percent of isolates belonged to six STs, including the high-risk clones ST-111, ST-175 and ST-235. Conclusions: MDR/XDR isolates were highly prevalent, particularly in Greece. The most effective antibiotic against P. aeruginosa was colistin, followed by ceftolozane/tazobactam and ceftazidime/avibactam. blaVIM-2 is associated with resistance to ceftolozane/tazobactam and ceftazidime/avibactam, and related to highly resistant phenotypes. ST-111 was the most frequent and disseminated clone and the clonal diversity was lower in XDR and PDR strains., This work was supported by the MagicBullet study. The European Union Directorate-General funded MagicBullet for Research and Innovation through the Seventh Framework Program for Research and Development (grant agreement 278232). Funding was also provided by the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion, Spanish Network for Research in Infectious Diseases (RD16/0016/0006) – co-financed by European Development Regional Fund ‘A way to achieve Europe'. This work was supported by the Fondo de Investigación Sanitaria (grant PI15/00860 to G. B.), integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII). A. P. was supported by grant IJCI-2016-29524.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies

  • González de Aledo, Manuel
  • González-Bardanca, Mónica
  • Blasco, Lucía
  • Pacios Santamaría, Olga
  • Bleriot Rial, Inés
  • Fernández-García, Laura
  • Fernández-Quejo, Melisa
  • López Díaz, María
  • Bou, Germán
  • Tomás, María
This article belongs to the Special Issue Non-antimicrobial Agents as Adjuvants against Bacterial Infections, [Abstract] One of the biggest threats we face globally is the emergence of antimicrobial-resistant (AMR) bacteria, which runs in parallel with the lack in the development of new antimicrobials. Among these AMR bacteria pathogens belonging to the ESKAPE group can be highlighted (Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) due to their profile of drug resistance and virulence. Therefore, innovative lines of treatment must be developed for these bacteria. In this review, we summarize the different strategies for the treatment and study of molecular mechanisms of AMR in the ESKAPE pathogens based on the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins’ technologies: loss of plasmid or cellular viability, random mutation or gene deletion as well directed mutations that lead to a gene’s loss of function., This study was funded by grants PI16/01163 and PI19/00878 awarded to M. Tomás within the State Plan for R+D+I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research-European Regional Development Fund “A way of Making Europe” and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0006) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/, Accessed on 21 June 2021). I. Bleriot was financially supported by pFIS program (ISCIII, FI20/00302). O. Pacios and M. López was financially supported by a grant IN606A-2020/035 and IN606B-2018/008, respectively, (GAIN, Xunta de Galicia), and M. Gonzalez-Bardanca was financially supported by the Rio Hortega program (ISCIII, CM20/00198), Xunta de Galicia; IN606A-2020/035, Xunta de Galicia; IN606B-2018/008
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CRISPR-Cas13a-Based Assay for Accurate Detection of OXA-48 and GES Carbapenemases

  • Ortiz-Cartagena, Concha
  • Pablo-Marcos, Daniel
  • Fernández-García, Laura
  • Blasco, Lucía
  • Pacios, Olga
  • Bleriot, Inés
  • Siller, María
  • López, María
  • Fernández, Javier
  • Aracil, Belén
  • Fraile-Ribot, Pablo Arturo
  • García-Fernández, Sergio
  • Fernández-Cuenca, Felipe
  • Hernández-García, Marta
  • Cantón, Rafael
  • Calvo-Montes, Jorge
  • Tomás, María
© 2023 Ortiz-Cartagena et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license., Carbapenem-resistant pathogens have been recognized as a health concern as they are both difficult to treat and detect in clinical microbiology laboratories. Researchers are making great efforts to develop highly specific, sensitive, accurate, and rapid diagnostic techniques, required to prevent the spread of these microorganisms and improve the prognosis of patients. In this context, CRISPR-Cas systems are proposed as promising tools for the development of diagnostic methods due to their high specificity; the Cas13a endonuclease can discriminate single nucleotide changes and displays collateral cleavage activity against single-stranded RNA molecules when activated. This technology is usually combined with isothermal pre-amplification reactions in order to increase its sensitivity. We have developed a new LAMP-CRISPR-Cas13a-based assay for the detection of OXA-48 and GES carbapenemases in clinical samples without the need for nucleic acid purification and concentration. To evaluate the assay, we used 68 OXA-48-like-producing Klebsiella pneumoniae clinical isolates as well as 64 Enterobacter cloacae complex GES-6, 14 Pseudomonas aeruginosa GES-5, 9 Serratia marcescens GES-6, 5 P. aeruginosa GES-6, and 3 P. aeruginosa (GES-15, GES-27, and GES-40) and 1 K. pneumoniae GES-2 isolates. The assay, which takes less than 2 h and costs approximately 10 € per reaction, exhibited 100% specificity and sensitivity (99% confidence interval [CI]) for both OXA-48 and all GES carbapenemases. IMPORTANCE Carbapenems are one of the last-resort antibiotics for defense against multidrug-resistant pathogens. Multiple nucleic acid amplification methods, including multiplex PCR, multiplex loop-mediated isothermal amplification (LAMP) and multiplex RPAs, can achieve rapid, accurate, and simultaneous detection of several resistance genes to carbapenems in a single reaction. However, these assays need thermal cycling steps and specialized instruments, giving them limited application in the field. In this work, we adapted with high specificity and sensitivity values, a new LAMP CRISPR-Cas13a-based assay for the detection of OXA-48 and GES carbapenemases in clinical samples without the need for RNA extraction., This study was funded by grants PI19/00878 and PI22/00323 awarded to M. Tomás, within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008-2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research - European Regional Development Fund “A Way of Making Europe” and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0006 and CIBER CB21/13/00012, CB21/13/00084 and CB21/13/00095), Instituto de Salud Carlos III FEDER. The research was also funded by grant IN607D 2021/10 within the GAIN (Agencia Gallega de Innovación) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/), and finally an ESCMID grant (European Society of Clinical Microbiology and Infectious Diseases) awarded to L. Fernández-García. O. Pacios, L. Fernández-García, and M. López were financially supported by the grants IN606A-2020/035, IN606B-2021/013 and IN606C-2022/002, respectively (GAIN, Xunta de Galicia). D. Pablo-Marcos was financially supported by a López Albo grant. I. Bleriot was financially supported by pFIS pro- 511 g (ISCIII, FI20/00302)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Proteomic Study of the Interactions between Phages and the Bacterial Host Klebsiella pneumoniae

  • Bleriot, Inés
  • Blasco, Lucía
  • Pacios, Olga
  • Fernández-García, Laura
  • López, María
  • Ortiz-Cartagena, Concha
  • Barrio-Pujante, Antonio
  • Fernández-C
  • Pascual, Álvaro
  • Martínez-Martínez, Luis
  • Oteo-Iglesias, Jesús
  • Tomás, María
© 2023 Bleriot et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license., Phages and bacteria have acquired resistance mechanisms for protection. In this context, the aims of the present study were to analyze the proteins isolated from 21 novel lytic phages of Klebsiella pneumoniae in search of defense mechanisms against bacteria and also to determine the infective capacity of the phages. A proteomic study was also conducted to investigate the defense mechanisms of two clinical isolates of K. pneumoniae infected by phages. For this purpose, the 21 lytic phages were sequenced and de novo assembled. The host range was determined in a collection of 47 clinical isolates of K. pneumoniae, revealing the variable infective capacity of the phages. Genome sequencing showed that all of the phages were lytic phages belonging to the order Caudovirales. Phage sequence analysis revealed that the proteins were organized in functional modules within the genome. Although most of the proteins have unknown functions, multiple proteins were associated with defense mechanisms against bacteria, including the restriction-modification system, the toxin-antitoxin system, evasion of DNA degradation, blocking of host restriction and modification, the orphan CRISPR-Cas system, and the anti-CRISPR system. Proteomic study of the phage-host interactions (i.e., between isolates K3574 and K3320, which have intact CRISPR-Cas systems, and phages vB_KpnS-VAC35 and vB_KpnM-VAC36, respectively) revealed the presence of several defense mechanisms against phage infection (prophage, defense/virulence/resistance, oxidative stress and plasmid proteins) in the bacteria, and of the Acr candidate (anti-CRISPR protein) in the phages., This study was funded by grant PI19/00878 and PI22/00323 awarded to M.T. within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development, and Innovation 2008-2011) and cofinanced by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research/European Regional Development Fund “A Way of Making Europe” and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI; RD16/0016/0006 and RD16/0016/0008), CIBERINFEC (CIBER21/13/00012, CB21/13/00049, CIBER21/13/00084, and CIBER21/13/00095), and Personalized Medicine Project (MePRAM; PMP/00092) and also by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC; http://www.seimc.org/). M.T. was financially supported by the Miguel Servet Research Program (SERGAS and ISCIII). I.B. was financially supported by pFIS program (ISCIII, FI20/00302). O.P., L.F.-G., and M.L. were financially supported by grants IN606A-2020/035, IN606B-2021/013, and IN606C-2022/002, respectively (GAIN; Xunta de Galicia)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genomic analysis of 40 prophages located in the genomes of 16 carbapenemase-producing clinical strains of Klebsiella pneumoniae

  • Bleriot, Ines
  • Trastoy, Rocío|||0000-0003-4580-7126
  • Blasco, Lucía|||0000-0002-4039-4142
  • Fernández-Cuenca, Felipe
  • Ambroa, Antón|||0000-0002-3525-2553
  • Fernández-García, Laura|||0000-0002-8531-6105
  • Pacios, Olga|||0000-0002-4476-856X
  • Perez-Nadales, Elena
  • Torre-Cisneros, J.|||0000-0003-1529-6302
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Miró, Elisenda|||0000-0003-2781-6926
  • Pascual Hernández, Álvaro|||0000-0002-8672-5891
  • Bou, German|||0000-0001-8837-0062
  • Martínez-Martínez, Luis
  • Tomas, Maria|||0000-0003-4501-0387
Klebsiella pneumoniae is the clinically most important species within the genus and, as a result of the continuous emergence of multi-drug resistant (MDR) strains, the cause of severe nosocomial infections. The decline in the effectiveness of antibiotic treatments for infections caused by MDR bacteria has generated particular interest in the study of bacteriophages. In this study, we characterized a total of 40 temperate bacteriophages (prophages) with a genome range of 11.454-84.199 kb, predicted from 16 carbapenemase-producing clinical strains of belonging to different sequence types, previously identified by multilocus sequence typing. These prophages were grouped into the three families in the order Caudovirales (27 prophages belonging to the family Myoviridae, 10 prophages belonging to the family Siphoviridae and 3 prophages belonging to the family Podoviridae). Genomic comparison of the 40 prophage genomes led to the identification of four prophages isolated from different strains and of genome sizes of around 33.3, 36.1, 39.6 and 42.6 kb. These prophages showed sequence similarities (query cover.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Sola-Campoy, Pedro J.
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • González, Mónica
  • Gracia-Ahufinger, Irene
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Mulet, Xavier
  • Pitart, Cristina|||0000-0002-3083-7915
  • Rivera, Alba|||0000-0002-9709-6162
  • Bou, German|||0000-0001-8837-0062
  • Calvo, Jorge
  • Cantón, Rafael|||0000-0003-1675-3173
  • González-López, Juanjo|||0000-0003-2419-5909
  • Martínez-Martínez, Luis
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oliver, Antonio|||0000-0001-9327-1894
  • Palacios-Baena, Zaira R.|||0000-0002-1713-6807
  • Pascual Hernández, Álvaro|||0000-0002-8672-5891
  • Ruiz-Carrascoso, Guillermo
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Aracil, Belén
  • Pérez-Vázquez, María
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical distribution, phylogeny, and resistance mechanisms in Spain. Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens

  • Blasco, Lucía|||0000-0002-4039-4142
  • Ambroa, Anton
  • Trastoy, Rocio
  • Bleriot, Ines
  • Moscoso, Miriam
  • Fernández-García, Laura|||0000-0002-8531-6105
  • Perez-Nadales, Elena
  • Fernández-Cuenca, Felipe
  • Torre-Cisneros, J.|||0000-0003-1529-6302
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Oliver, Antonio|||0000-0001-9327-1894
  • Cantón, Rafael|||0000-0003-1675-3173
  • Kidd, Tim
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Miró, Elisenda|||0000-0003-2781-6926
  • Pascual Hernández, Álvaro|||0000-0002-8672-5891
  • Bou, German|||0000-0001-8837-0062
  • Martínez-Martínez, Luis
  • Tomas, Maria|||0000-0003-4501-0387
The emergence of multidrug resistant (MDR) pathogenic bacteria is jeopardizing the value of antimicrobials, which had previously changed the course of medical science. In this study, we identified endolysins ElyA1 and ElyA2 (GH108-PG3 family), present in the genome of bacteriophages Ab1051Φ and Ab1052Φ, respectively. The muralytic activity of these endolysins against MDR clinical isolates (Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae) was tested using the turbidity reduction assay. Minimal inhibitory concentrations (MICs) of endolysin, colistin and a combination of endolysin and colistin were determined, and the antimicrobial activity of each treatment was confirmed by time kill curves. Endolysin ElyA1 displayed activity against all 25 strains of A. baumannii and P. aeruginosa tested and against 13 out of 17 strains of K. pneumoniae. Endolysin ElyA2 did not display any such activity. The combined antimicrobial activity of colistin and ElyA1 yielded a reduction in the colistin MIC for all strains studied, except K. pneumoniae. These results were confirmed in vivo in G. mellonella survival assays and in murine skin and lung infection models. In conclusion, combining colistin (1/4 MIC) with the new endolysin ElyA1 (350 µg) enhanced the bactericidal activity of colistin in both in vitro and in vivo studies. This will potentially enable reduction of the dose of colistin used in clinical practice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems, Recomendaciones del Comité Español del Antibiograma (COESANT) para la selección de antimicrobianos y sus concentraciones en el estudio in vitro de la sensibilidad con métodos automáticos

  • Cantón, Rafael|||0000-0003-1675-3173
  • Oliver, Antonio|||0000-0001-9327-1894
  • Alós, Juan Ignacio
  • Benito, Natividad|||0000-0001-6410-013X
  • Bou, German|||0000-0001-8837-0062
  • Campos, José
  • Calvo, Jorge
  • Canut-Blasco, Andrés
  • Castillo, Javier
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Domínguez, Maria Ángeles
  • Fernández-Cuenca, Felipe
  • Guinea, Jesús
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Liñares, Josefina
  • López-Cerero, Lorena
  • López-Navas, Antonio
  • Marco, Francesc|||0000-0002-1863-6379
  • Mirelis, Beatriz
  • Moreno-Romo, Miguel Ángel
  • Morosini, María Isabel
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Pascual Leone, Álvaro|||0000-0001-8975-0382
  • Pérez Trallero, Emilio
  • Pérez-Vázquez, María
  • Soriano Viladomiu, Alex|||0000-0002-9374-0811
  • Torres, Carmen
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Martínez-Martínez, Luis
Automated antimicrobial susceptibility testing devices are widely implemented in clinical microbiology laboratories in Spain, mainly using EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoints. In 2007, a group of experts published recommendations for including antimicrobial agents and selecting concentrations in these systems. Under the patronage of the Spanish Antibiogram Committee (Comité Español del Antibiograma, COESANT) and the Study Group on Mechanisms of Action and Resistance to Antimicrobial Agents (GEMARA) from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), and aligned with the Spanish National Plan against Antimicrobial Resistance (PRAN), a group of experts have updated this document. The main modifications from the previous version comprise the inclusion of new antimicrobial agents, adaptation of the ranges of concentrations to cover the EUCAST breakpoints and epidemiological cut-off values (ECOFFs), and the inference of new resistance mechanisms. This proposal should be considered by different manufacturers and users when designing new panels or cards. In addition, recommendations for selective reporting are also included. With this approach, the implementation of EUCAST breakpoints will be easier, increasing the quality of antimicrobial susceptibility testing data and their microbiological interpretation. It will also benefit epidemiological surveillance studies as well as the clinical use of antimicrobials aligned with antimicrobial stewardship programs., Los sistemas automáticos utilizados en el estudio de la sensibilidad a los antimicrobianos están introducidos en la mayoría de los laboratorios de Microbiología Clínica en España, utilizando principalmente los puntos de corte del European Committee on Antimicrobial Susceptibility Testing (EUCAST). En 2007, un grupo de expertos publicó unas recomendaciones para incluir antimicrobianos y seleccionar concentraciones en estos sistemas. Bajo el auspicio del Comité Español del Antibiograma (COESANT) y del Grupo de Estudio de los Mecanismos de Acción y Resistencia a los Antimicrobianos (GEMARA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y alineado con el Plan Nacional frente a la Resistencia a los Antibióticos (PRAN), un grupo de expertos ha actualizado dicho documento. Las principales modificaciones realizadas sobre la versión anterior comprenden la inclusión de nuevos agentes antimicrobianos, la adaptación de los rangos de concentraciones para cubrir los puntos de corte clínicos y los puntos de corte epidemiológicos (ECOFF) definidos por el EUCAST, y para la inferencia de nuevos mecanismos de resistencia. Esta propuesta debería ser considerada por los diferentes fabricantes y los usuarios cuando se diseñen nuevos paneles o tarjetas. Además, se incluyen recomendaciones para realizar informes selectivos. Con este enfoque, la implementación de los puntos de corte del EUCAST será más fácil, aumentando la calidad de los datos del antibiograma y su interpretación microbiológica. También será de utilidad para los estudios de vigilancia epidemiológica, así como para el uso clínico de los antimicrobianos, de acuerdo con los programas de optimización de uso de antimicrobianos (PROA).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased Antimicrobial Resistance in a Novel CMY-54 AmpC-Type Enzyme with a GluLeu217-218 Insertion in the Ω-Loop

  • Pérez-Llarena, Francisco José
  • Vázquez-Ucha, Juan Carlos
  • Kerff, Frédéric
  • Zamorano, Laura
  • Miró, Elisenda|||0000-0003-2781-6926
  • Cabral, María Póvoa
  • Fleites, Ana
  • Lantero, Marta
  • Martínez-Martínez, Luis
  • Oliver, Antonio|||0000-0001-9327-1894
  • Galleni, Moreno
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Beceiro, Alejandro
  • Bou, German|||0000-0001-8837-0062
During a Spanish surveillance study, a natural variant of a CMY-type β-lactamase related to CMY-2 with a GluLeu217-218 insertion in the Ω-loop (designated CMY-54) was found to increase the minimum inhibitory concentractions to β-lactams in a clinical strain of Escherichia coli. The aim of this study was to characterize CMY-54 by genetic, microbiological, and biochemical analysis. The blaCMY-54 gene is encoded by a plasmid of around 100 kb that hybridizes with K and FIB probes. The genetic context of blaCMY-54 and blaCMY-2 genes was found to be very similar. E. coli expressing CMY-54 under isogenic conditions showed a clear fourfold to eightfold increase in MICs to penicillins, cefotaxime, ceftazidime, and aztreonam compared with CMY-2. The catalytic efficiencies of pure CMY-2 and CMY-54 proteins correlated with their microbiological parameters. CMY-2 protein was more resistant to thermal denaturation than CMY-54, indicating that the Ω-loop of CMY-54 may be wider and more relaxed and probably enables better accommodation of these antimicrobials. Otherwise, the higher stabilization of CMY-2 may induce a slight reduction of the dynamics of this enzyme and primarily affect the hydrolysis of some of the bulkiest antibiotics. In summary, the GluLeu217-218 insertion observed in CMY-54 compared to CMY-2 produces a β-lactamase with a distinctive catalytic efficacy for β-lactam antimicrobials likely caused by an increased flexibility slightly affecting the active site shape, highlighting the relevance of single mutations on the hydrolytic spectrum in class C β-lactamases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Corrigendum, CARB-ES-19 multicenter study of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli from all Spanish provinces reveals interregional spread of high-risk clones such as ST307/OXA-48 and ST512/KPC-3

  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Sola-Campoy, Pedro J.
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • González, Mónica
  • Gracia-Ahufinger, Irene
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Mulet, Xavier
  • Pitart, Cristina|||0000-0002-3083-7915
  • Rivera, Alba|||0000-0002-9709-6162
  • Bou, German|||0000-0001-8837-0062
  • Calvo, Jorge
  • Cantón, Rafael|||0000-0003-1675-3173
  • González-López, Juanjo|||0000-0003-2419-5909
  • Martínez-Martínez, Luis
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oliver, Antonio|||0000-0001-9327-1894
  • Palacios-Baena, Zaira R.|||0000-0002-1713-6807
  • Pascual, Álvaro
  • Ruiz-Carrascoso, Guillermo
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Aracil, Belén
  • Pérez-Vázquez, María
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
[This corrects the article DOI: 10.3389/fmicb.2022.918362.].